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1. Introduction 
 
 
The central nervous system (CNS), unlike many other tissues, has a limited capacity for self-
repair. Damaged mature nerve cells lack the ability to regenerate, and although endogenous 
neural stem cells exist even in the adult brain, their ability to generate new functional neurons 
in response to injury is very limited. For this reason, there is great interest in the possibility of 
repairing the nervous system by transplanting new cells that might replace those lost through 
damage or disease. This strategy has been studied in many models for neurodegenerative 
diseases with a variety of cell and tissue types that have been transplanted. In this work, I 
would like to report on the experiments of neural stem cell transplantations into mouse 
models for Huntington´s disease. 
 
 
1.1. Huntington´s Disease 
Huntington’s disease (HD) is an autosomal dominantly inherited neurodegenerative 
disorder which was first described by George Huntington in 1872 (Huntington, 1872). HD 
affects 5-10 per 100,000 people with a fairly even prevalence throughout the world 
(Meierkord et al., 1994). In most cases, the disease strikes around an age of 40 years with 
the first clinical presentations including chorea (involuntary jerky movements), which is the 
hallmark of the disease. A very rare juvenile form of HD, starting around the age of 20 years, 
has also been described with different initial symptoms such as rigidity, dystonia (sustained 
muscular contractions) and epilepsy (Westphal, 1883). Although the motor symptoms lead to 
the diagnosis of HD, the early course of the disease is characterized by psychiatric 
symptoms such as depression and a shift of the patient´s personality. In the later phase of 
the disorder the patients also suffer from dementia and very severe motor restrictions such 
as bradykinesia (slowness of movements) and akinesia (lack of movements). Although the 
symptomatology can vary markedly between patients, HD progresses inexorably to death 
within 10-20 years of diagnosis and even more rapidly in juveniles. 
In terms of brain pathology, projection neurons of the striatum are most severely affected, 
resulting in a progressive atrophy of the caudate nucleus, putamen, and globus pallidus (Fig. 
1.1). There is also pronounced atrophy in the cerebral cortex which explains the dramatic 
brain weight loss of 25-30% in later disease stages (Vonsattel et al., 1985). The 
neurodegenerative process in the striatum is very selective, so that only the GABAergic 
medium sized spiny neurons that project to the globus pallidus and nucleus subthalamicus 
are affected while the interneurons, of which several subtypes have been identified, remain 
unaffected (Cicchetti and Parent, 1996; Ferrante et al., 1987; Harrington and Kowall, 1991). 
The striatal neurodegeneration is accompanied by an increasing astrogliosis. 
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  Figure 1.1. Brain structures mostly affected in HD 
Representation of a parasagittal sectioned human brain (Nettes 
Neurologie, Thieme Verlag). Neurodegeneration of the neostriatum 
(nucleus caudatus and putamen) and the globus pallidus as well as the 
cortex results in an atrophy of the brain. 
 
The selective cell death in the basal ganglia determines the occurrence of the different motor 
symptoms of Chorea Huntington (Albin et al., 1989). The early loss of inhibitory striatal 
neurons that project to the lateral globus pallidus, leads to a functional inhibition of the 
nucleus subthalamicus which results in a lack of inhibition of the substantia nigra and medial 
globus pallidus. The loss of inhibition of these structures then leads to an enhanced activity 
of the excitatory thalamocortical projections which in turn leads to a disinhibition of cortical 
motor neurons and in the end induces the typical involuntary movements (Fig. 1.2). 
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2 Figure 1.2. Functional diagram of the 
basal ganglia circuits 
Striatal projections affect the substantia 
nigra pars reticulata (SNr) and the medial 
globus pallidus (MGP) by two different 
circuits (excitatory projections = black; 
inhibitory projections = red). One indirect 
circuit effects an inhibition of the lateral 
globus pallidus (LGP) which leads to a
decrease of the subsequent inhibition of 
the nucleus subthalamicus (STN). The 
reduced inhibition of the STN then effects 
an increased excitatory activation of both, 
the MGP and the SNr. The second circuit 
is a direct striatal inhibition of the MGP and 
SNr. The balance of these two circuits 
controls the inhibition of the ventrolateral 
thalamus. 
The underlying cause of HD is the expansion of a CAG repeat sequence in the first exon of a 
gene on chromosome 4p16.3, encoding the protein huntingtin (Gusella et al., 1983). CAG is 
one of the codons for glutamine. The normal range for the number of glutamines in the 
polyglutamine tract is between 6 and 34, with disease processes beginning when the 
polyglutamine tract is greater than 35. The highest amount of triplet repeats is found in 
juvenile Chorea Huntington: Higher CAG repeat numbers predestine to an earlier disease 
onset. Huntingtin is a cytoplasmic protein which, under normal conditions, is not found in the 
nucleus normally. Its function is, at present, not clearly understood but the molecule might 
serve as a shuttle protein binding intracellular vesicles to the cytoskeleton (DiFiglia et al., 
1995). One hypothesis about the disease mechanism is the so called `gain of function´ 
theory which assumes that the normal function of the huntingtin protein is not influenced by 
the gene defect, but an additional function of the abnormal protein causes the pathology 
(Sharp and Ross, 1996). The abnormal huntingtin protein which is modified by the elongated 
polyglutamine tract tends to establish intramolecular connections. While folding in a certain 
manner the protein presents other binding sites to neighbouring huntingtin molecules and 
intermolecular connections are built. This `zipper theory´ explains the aggregation of several 
proteins (Fig. 1.3).  
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Figure 1.3. Schematic representation of the `zipper theory´ of aggregate-synthesis 
a) Two huntingtin molecules, each with a polyglutamine tract. b) Outlined protein form (red 
lines) after intramolecular (orange lines) and intermolecular (brown lines) connections are 
built. c) Photograph of the electron microscopic presentation of huntingtin aggregates 
taken from the manuscript of (Scherzinger et al., 1997). 
 
The amyloid-like aggregates result in microscopically visible inclusions within neuronal nuclei 
and dystrophic neurites in the brain of HD patients (DiFiglia et al., 1997). The formation of 
nuclear aggregates is associated with several cellular dysfunctions. One of them is a shift in 
the core catalytic component of the proteosome to the nucleus. Thus, the formation of 
nuclear aggregates reduces the availability of the proteosome for the digestion of other 
intracellular proteins that need to be removed, such as the apoptosis promoting protein p53 
(Jana et al., 2001). Another disturbance in cell function is caused by the binding of important 
transcription factors (such as CBP and TATA) to the aggregates that leads to a multiple 
transcriptional interference (Cha, 2000). However, it is unclear whether the formation of 
aggregates per se is the essential cytotoxic step or a consequence of cellular dysfunction. 
HD is inherited in a standard Mendelian autosomal pattern where offspring have a 50% 
chance of being affected when one of their parents carries the mutation. The mutation is fully 
penetrant such that over 99% of people with the mutation develop the disease and although 
it was already identified in 1993, the disease mechanism is not entirely understood and there 
is, as is true for all neurodegenerative diseases, no curative therapy available (The 
Huntington's Disease Collaborative Research Group, 1993).  
 
 
1.2. Animal models 
In order to investigate restorative therapies via stem cell replacement in HD, it is 
essential to use animal models which closely resemble the striatal neuropathological 
characteristics of this disorder, i.e. selective neurodegeneration of GABAergic projection 
neurons with relative sparing of interneurons (Li, 1999; Sharp and Ross, 1996) as well as 
striatal astrogliosis. Stereotactic injection of glutamate agonists, such as quinolinic acid (QA) 
into the striatum is the most commonly used approach to investigate HD in animal models, 
since glutamatergic excitotoxic cell damage has been postulated to play a role in the 
pathogenesis of HD and also because it reproduces the selective loss of striatal GABAergic 
projection neurons (Beal et al., 1986; Beal et al., 1989). A single intrastriatal infusion of QA 
produces striatal cell degeneration that largely occurs within 7 days (Waldvogel et al., 1991). 
The peak of cell death occurs in the first 3 days (Portera-Cailliau et al., 1995). Furthermore, 
behavioural abnormalities and electrophysiological changes characteristic for HD could be 
observed in this type of animal model (Block et al., 1993; Portera-Cailliau et al., 1995). 
Although the QA-lesioned animals do not display any constant motor restrictions, functional 
improvements after experimental therapeutic strategies can still be investigated since there 
are several behavioural tests that can be conducted after either a unilateral or a bilateral 
lesion of the striatum. The most common test is drug-induced rotation behaviour, which is 
performed after a unilateral QA-injection. After an intra-peritoneal injection of apomorphin (a 
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dopamine-agonist) or amphetamine (which increases the dopamine-concentration in the 
synaptic cleft), the imbalance of basal ganglia activity caused by the lesion is dramatically 
enhanced and the animals rotate in a direction ipsilateral to the lesioned side (Fricker et al., 
1996). Another fairly often used behavioural test assesses asymmetry in the use of forelimbs, 
seen in the natural exploratory behaviour of the animals (also see chapter 2.6). 
More recently, transgenic mouse models of HD have been established expressing the 
causative mutation with an expanded CAG repeat tract (Davies et al., 1997; Mangiarini et al., 
1996). At 9-11 weeks of age, these mice show a choreic-like movement dysfunction plus 
tremor, involuntary stereotypes, and stimulus-induced seizures. Mice die suddenly at 12-16 
weeks of age. Although the brains of the transgenic mice are smaller than normal, there is no 
evidence of neuronal loss in the striatum or other regions. However, the characteristic 
neuronal intranuclear inclusions are found in the striatum and other regions of the brain and 
are specifically localized to striatal medium sized neurons. Although these transgenic mice 
represent an extremely valuable tool especially for the study of the intranuclear inclusions 
and corresponding molecular abnormalities, they are not well suited for traditional neuronal 
rescue or replacement strategies, because of the lack of neuronal cell loss. 
 
 
1.3. Cell replacement strategies 
Since in early disease stages, neurodegeneration is mainly confined to a distinct 
population of GABAergic projection neurons within the striatum, cell replacement therapies 
have been proposed for the treatment of HD (Brasted et al., 1999; Clarke et al., 1988; 
Dunnett et al., 1988; Sirinathsinghji et al., 1988). 
There are, of course different possibilities of replacing the degenerating and dying neurons. 
The easiest and best way of replacing the striatal neurons would be by neurogenesis. During 
the past decade, it has become well accepted that neurogenesis persists in hippocampus, 
subventricular zone, and possibly other areas of the adult CNS in a variety of mammalian 
species, including humans (Eriksson et al., 1998; Lois and Alvarez-Buylla, 1993). In the case 
of HD, Curtis and colleagues reported an increased cell proliferation as well as neurogenesis 
in the brain of HD patients post mortem, suggesting that an intrinsic repair mechanism might 
already exist (Curtis et al., 2003). But since the newborn cells will also carry the gene defect, 
they might not be able to replace the dying cells for a long time. Obviously this mechanism is 
not very effective and in order to become a therapeutic strategy, needs to be strongly 
enhanced. 
More successful experimental approaches using fetal tissue from the ganglionic eminence as 
a cell replacement source, have been studied by many groups over the last 20 years 
(Giordano et al., 1988; Olsson et al., 1995; Rosser et al., 2002; Sanberg et al., 1990). 
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Grafted progenitor cells from the striatal primordia of the developing forebrain form a striatal-
like structure at the site of implantation. Some of these cells differentiate into mature striatal 
projection neurons, which establish functional GABAergic innervation in the denervated 
globus pallidus and receive synaptic inputs from cortex, thalamus and substantia nigra 
(Bjorklund et al., 1994; Dunnett, 1995). The transplantation studies with fetal tissue also 
proved the reverse of lesion-induced deficits in both motor and cognitive behaviour, not only 
in rats but also in the larger and more complex striatal system of monkeys (Kendall et al., 
1998; Palfi et al., 1998). Thus, they resulted in ongoing clinical trials (Bachoud-Levi et al., 
2000; Peschanski et al., 2004). However, the use of human fetal tissue has raised a number 
of ethical concerns and the availability of material is rather limited. Several researchers have 
thus started to investigate neural stem cells as an alternative source for cell replacement 
therapy in HD (Eriksson et al., 2003; Fricker et al., 1999; Fricker-Gates et al., 2004; 
Hurelbrink et al., 2002; McBride et al., 2004). Given the capacity to self-renew and ability to 
differentiate efficiently into the desired cell type, it is anticipated that clonal populations of 
neural stem cells will produce similar, if not greater beneficial effects, while being more 
amenable to manipulation, enrichment and expansion. Nonetheless, the functional 
integration of donor cells remains a highly demanding challenge that requires a profound 
understanding and control of the biological properties of both donor cells and the interaction 
with the host environment. 
 
 
1.4. Stem cells  
The term “stem cell” is generally used to describe a cell that is capable of both self-
renewal and differentiation. There are several types of stem cells, depending on the origin 
and the potency of differentiation into various cell types. They may originate from embryos, 
aborted fetuses, umbilical cord blood, and adult organs and tissues. 
 
Embryonic stem cell (ESC) 
The most potent stem cells derive from the blastocyst, a mammalian embryo before 
implantation. Blastocysts consist of outer trophoderm cells, which allow the embryo to 
implant, surrounding the inner cell mass, within which the pluripotent epiblast cells are found. 
Pluripotent cells are able to give rise to all cell types found in the embryo and adult animal. 
This great differentiation potential is of course an advantage, but also bears the 
disadvantage of possible teratoma formation after transplantation in vivo. Since these cells 
can easily be genetically modified, they implicit a great potential for many different 
therapeutic strategies. One example was investigated in this study, when ESCs were 
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transfected with L1, a cell adhesion molecule that has been demonstrated to positively 
influence both, differentiation and migration of the stem cells after transplantation. 
 
Neural stem cell (NSC) 
Neural stem cells are a subtype of progenitor cells in the nervous system that can 
self-renew and generate both neurons and glia. They arise from specific germinative zones 
in the embryonic and adult mammalian CNS (Weissman et al., 2001). Neural stem cells 
seem to have a proliferative response mainly to epidermal growth factor (EGF) and basic 
fibroblast growth factor (bFGF), although other factors might have an additional influence 
(Alvarez-Buylla and Temple, 1998). These multipotent cells give rise to more restricted 
precursor cells, which in turn generate the main cell classes in the brain (Fig. 1.4; Gage, 
2000). Initially, neural stem cells express nestin, an intermediate filament and marker of 
neuro-epithelial stem cells. Following differentiation, cells with neuronal morphology express 
the neuronal markers type III beta tubulin, microtubule associated protein 2 (MAP-2) and a 
marker specific for neuronal nuclei (NeuN). Cells with astrocytic morphology express glial 
fibrillary acidic protein (GFAP) and cells with oligodendrocytic morphology express cyclic 
nucleotide 3´-phosphodiesterase (CNPase) and the cell surface molecule O4 respectively 
(Reynolds and Weiss, 1996; Reynolds and Weiss, 1992; Weiss, 1999; Weiss and van der 
Kooy, 1998).
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Figure 1.4. Progressive restriction of a NSC during the development
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Adult stem cells 
In the adult, stem cells were first defined in tissues with a high cell turnover, such as 
skin and gut. More recently, they have also been identified in tissues with no or low 
regenerative potential and cell turnover. Stem cells derived from fetal or adult tissue no 
longer possess the ability to differentiate into all cell types but are more restricted, 
differentiating into a limited range of cell types. Therefore they are called multipotent, 
meaning that they can give rise to more than one differentiated cell type. The clearest 
examples of areas in which neural stem cells appear to reside are the subventricular zone of 
the forebrain and the dentate gyrus of the hippocampus. In vitro these cells can produce 
neurons, astrocytes, and oligodendrocytes (Lois and Alvarez-Buylla, 1993). 
 
 
1.5. Important parameters for a successful stem cell therapy 
Transplantation of stem cells as a therapeutic approach for neurodegenerative 
diseases demands several important requirements. The cells must survive inside the host 
tissue for a long time and they need to differentiate and integrate into the cellular circuits of 
the host in order to replace lost neurons and their function.  
Experiments with neural stem cell transplants into the QA lesioned striatum have shown that 
cell survival is, by far, not as good as the survival of fetal tissue transplants (Lundberg et al., 
1997; Svendsen et al., 1996). Thus, it is crucial to identify the factors that potentially increase 
graft survival. One of the critical factors which may influence cell survival, is the method of 
stem cell preparation in vitro prior to transplantation. In culture, neural stem cells grow as 
free-floating aggregates, termed neurospheres (Reynolds et al., 1992; Reynolds and Weiss, 
1992). Some groups dissociate these cells via different techniques before transplantation in 
order to promote better integration and possible migration into the host tissue whereas other 
groups transplant intact neurospheres (Ader et al., 2004; Ader et al., 2001; Carpenter et al., 
1997; Eriksson et al., 2003; Hammang et al., 1997; Winkler et al., 1998). 
Secondly, the survival of grafted neural stem cells may depend more on environmental 
factors than fetal transplants do, which are usually transplanted as a suspension of the entire 
striatal eminence (Dobrossy and Dunnett, 2004; Dunnett et al., 2000a; Dunnett and 
Bjorklund, 1992). However, the changes occurring in the host after striatal injection of QA are 
only partially understood. QA injection induces acute cell death of striatal projection neurons 
(Beal et al., 1986; Beal et al., 1989). In parallel, astrocytes react to the tissue damage by 
proliferation leading to striatal astrogliosis - a feature of HD pathology (Dusart et al., 1991; 
Isacson et al., 1987). Also activated microglia migrate into the lesioned striatal parenchyma 
and proliferate as a reaction to QA induced neuronal degeneration (Marty et al., 1991; 
Topper et al., 1993). This morphological disintegration of the normal striatal anatomic 
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architecture is accompanied by changes in the expression of a variety of inflammatory and 
neurotrophic factors (Acarin et al., 2000; Canals et al., 1998; Haas et al., 2004; Schiefer et 
al., 1998) which might affect the grafted cells. One of these growth factors, known to be of 
specific importance for differentiation and survival of striatal neurons, is brain-derived 
neurotrophic factor (BDNF; Mizuno et al., 1994; Nakao et al., 1995; Perez-Navarro et al., 
2000; Ventimiglia et al., 1995). 
Transplanted stem cells react to environmental cues. When grafted into non-neurogenic 
regions of the brain, they mostly fail to differentiate into neurons and therefore cannot 
connect to any afferent and efferent structures to rebuild lost circuits. Both, embryonic and 
adult NSCs differentiate primarly into glia when transplanted into non-neurogenic regions of 
adult CNS, such as the cerebral cortex, striatum, or spinal cord (Brasted et al., 1999; Cao et 
al., 2001; Chow et al., 2000). Thus, successful neuronal replacement may require 
transplanting cells that are already committed to a neuronal lineage rather than pluripotent 
stem cells. 
 
 
1.6. Goals 
The purpose of this study was to investigate NSC grafts after transplantation into two 
different mouse models for HD, the QA-lesion model and the transgenic R6/2 mouse. The 
two models mimic different aspects of HD and the differences of graft survival and 
differentiation in these models were investigated. In the QA model, (1) the influence of timing 
between lesion and transplantation and of the method of preparation of the graft (i.e. 
neurospheres vs. dissociated cell suspension) on the survival of donor cells in vivo was 
investigated and (2) the development of astrogliosis, microglial reaction and BDNF protein-
expression over time was observed to identify possible contributing factors of the host tissue 
to graft survival in the QA lesion model. Additionally, (3) the NSC differentiation in vivo after 
transplantation into both mouse models was estimated. Another aim of this study was (4) the 
behavioural analysis of QA-lesioned mice that had received an intrastriatal transplant of 
genetically manipulated embryonic neural stem cells (eNSC). This last project was carried 
out in cooperation with Marcel Dihné and Christian Bernreuther from the group of Prof. 
Melitta Schachner in Hamburg. 
 
 
 
 
 
9 
2. Material and Methods 
 
 
2.1. Animals  
The studies of therapeutic strategies for Huntington´s disease (HD) require 
experimental animal models and because the disease is restricted to humans, the 
experimental approach needs to be performed in mammalian species. There are several 
mouse and rat models imitating the neuropathology of HD. We chose the model of 
intrastriatal injection of quinolinic acid that is already well established in rats. Since we aimed 
to perform mouse stem cell transplantations without immunsuppression, we transformed the 
technique of stereotaxic injection from rat brain to the much smaller mouse skull. A total of 
eighty-three adult mice of both sexes were used for the QA-lesion and stem cell 
transplantation experiments. 
Another mouse model for HD used in this study was the R6/2 line of transgenic mice. It has 
been established by the group of Gill Bates in 1996 (Mangiarini et al., 1996). With an insert of 
the first exon of the human HD gene these mice show a progressive neurological phenotype 
and die in between 12-16 weeks of age. In sum, thirteen transgenic mice were used for stem 
cell transplantation experiments. 
Both, wild type (wt) and transgenic (tg) mice came from our in house breeding. Hemizygote 
ovarian transplanted wt females and wt males, both from the C57 BL/6J background, were 
purchased from the Jackson Laboratories (Bar Harbor, ME, USA) and kept under quarantine 
for two months until they were located in the S1 animal facilities of the Medical Hospital, 
RWTH-Aachen. Two to four weeks after pairing the first littermates were born. Because the 
gene defect is inherited dominantly, about 50% of the littermates were hemizygous 
transgenic mice. All animals were housed in standard cages under controlled temperature 
and a 12h light/dark cycle with free access to food and water. Animal protection regulations 
were applied and closely followed. 
 
 
2.2. Genotyping 
 
2.2.1. DNA isolation 
In order to identify the genotype of the littermates, the tail tip of each animal was cut 
at 2 weeks of age and processed for DNA isolation according to the standardized DNA 
Isolation Kit PURGENE® (Gentra Systems, Minneapolis, USA) following the manufacturer’s 
instructions for DNA isolation from 5 mm mouse tail tissue, page 42. 
DNA samples were stored at 4°C until PCR was performed. 
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2.2.2. PCR 
Polymerase chain reaction (PCR) is an in vitro method for enzymatic amplification of 
specific sequences of DNA. In the reaction two oligonucleotide primers hybridise to opposite 
strands and were designed to flank the inserted Exon 1 of the human HD gene. The primers 
were generated using software of Whithead Institute for Biomedical research (Cambridge, 
MA; http://www.genome.wi.mit.edu/cgi-bin/primer/primer3www.cgi) and synthesized at MWG 
Biotech. Primer sequences were as follows 5´-3´: CGG CTG AGG CAG CAG CGG CTG 
TGC; GCA GCA GCA GCA GCA ACA GCC GCC ACC. 
PCR was performed according to the following protocol: 
The reaction mix contained: 
• 5 µl of a ReadyMix REDTaq solution (SIGMA) containing 0.04 mM dNTP (dATP, 
dGTP, dCTP, dTTP), 0.03 units/µl REDTaq polymerase, 2 mM Tris-HCl, 10 mM KCl, 
0.3 mM MgCl2, 0.0002% gelatine and stabilisers. 
• 1 µl Dimethylsulfoxide (DMSO, SIGMA) 
• 2.5 µl H2O 
• 0.5 µl of each primer [10 µM] 
• 0.5 µl DNA1 
 
PCR was conducted on a Primus Thermal Cycler (MWG), reaction parameters were: 
• first denaturation 90 sec at 95°C 
• 35 cycles of annealing 20 sec at 68°C, extension 60 sec at 72°C, denaturation 30 sec 
at 94°C 
• last elongation 12 min at 72°C 
 
The separation of PCR products was performed by gel electrophoresis in a 3% Agarose 
(SIGMA) gel containing 0.005% GelStar® (BMA, Rockland, ME, USA). The product size was 
80 bp and visualisation was attended with the help of a UV-transilluminator (Biometra). 
 
 
2.3. Surgery 
All surgical processes were performed under S1 laboratory conditions in the animal 
facilities of the Medical Hospital, RWTH-Aachen. A stereotaxic frame was used for the 
intrastriatal injection of QA and stem cells. With help of “The Mouse Brain” (Academic press) 
the stereotaxic coordinates were evaluated in relation to bregma, the crossing point of the 
                                                 
1 Since only the detection of the transgene was aimed, the DNA samples were not quantified before 
processing for PCR. A volume of 0.5 µl of each DNA sample containing an unknown amount of DNA 
was analyzed.   
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mouse skull sutures (Fig. 2.3). After induction of inhalation anesthesia with 20% isofluoran2 
(Forene®, Abbot GmbH und Co. KG, Wiesbaden), the skull of the mouse was mounted in the 
stereotaxic frame by pulling the front teeth into a small hole of the jaw clip and fixing the 
temples with two small bench vices. With help of the thumb of a rubber glove that was pulled 
over the jaw clip, the inhalation gases could be directed to the mouth of the mouse. As soon 
as the skull was fixed, the eyes of the mouse were covered with Bepanthen® (Roche) to 
prevent dehydration. During all surgical processes, body temperature was controlled using a 
heating pad set at 37°C to prevent the animals from cooling. Because it is important to see 
the fissures on top of the skull, the skin was cut by a sagittal incision of 2 cm and the 
connective tissue underneath was scraped off. When the right coordinates for the injection 
are adjusted, a small hole is drilled with help of a sharp scalpel. Before the injection needle is 
brought in, the dura mater must be penetrated using a small canule. 
 
Fig. 2.3. Mouse skull diagram:                            
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2.3.1. Stereotaxic injection of quinolinic acid 
Quinolinic acid (C7H5NO4) was dissolved in 1 N sodium hydroxide, titrated with 
hydrochloric acid to pH 7.4 and then diluted in 0.1M phosphate buffered saline (PBS). Under 
deep inhalation anesthesia with a mixture of oxygen (O2) / nitroxide (N2O) (1:1) and 2-4% 
isofluoran, the mice received stereotaxic unilateral intrastriatal injections of 1 µl of 60 nM 
quinolinic acid using a 2 µl Hamilton micro syringe fitted with a glass micropipette (Hansson 
et al., 1999). Injections were made into the right striatum at the following stereotaxic 
coordinates from bregma: 0.4 mm rostral, 2.6 mm lateral, depth 3.2 mm from the skull 
surface. The toxin was injected over a period of 2 min, and thereafter, the micropipette was 
left in place for additional 3 min before it was withdrawn carefully.  
 
                                                 
2  1-Chloro-2,2,2-trifluoroethyldifluoromethylether 
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2.3.2. Stereotaxic injection of stem cells 
Wild type mice were transplanted using the same stereotaxic coordinates as for the 
QA lesion surgery. Because of the loss of body weight and the brain atrophy characteristic 
for the R6/2 tg mice, the coordinates for stereotaxic injection of stem cells into the striatum of 
tg mice were slightly changed to: 0.4 mm rostral, 2.2 mm lateral from bregma and a depth of 
3.2 mm from the skull surface. Following induction of anesthesia, the mice were kept 
anesthetized by inhalation as described before. 1 µl of the stem cell suspension was injected 
using a glass micropipette connected to a Hamilton syringe (2 µl). After injection of the cells, 
the micropipette was left in place for about 3 min before it was withdrawn carefully. 
 
 
2.4. Cell Culture 
All stem cells used in this study were kindly provided by the Centre of Molecular 
Neurobiology in Hamburg. The NSCs were isolated from embryonic brain tissue: C57BL/6J 
wild-type females were mated with EGFP-transgenic males (EGFP expression is regulated 
by the chicken beta-actin promotor and cytomegalovirus enhancer; Okabe et al., 1997) and 
pregnant animals were killed at day 14 of embryonic development. Striata from EGFP-
transgenic mouse embryos were mechanically dissociated, and 200,000 cells/ml were 
cultured in a serum-free medium (Ader et al., 2000) in the presence of epidermal growth 
factor (EGF) and basic fibroblast growth factor (bFGF; both at 10 ng/ml; SIGMA).  
Embryonic neural stem cells (eNSC) were isolated from blastocytes (Dihné et al., 2004) and 
transfected with a plasmid containing the full length murine L1 (Moos et al., 1988) under the 
influence of the promoter of the isoform I of the murine 3-phoshoglycerokinase (PGK). 
Maintenance of undifferentiatied ES cells, embryoid body formation, and selection of nestin-
positive cells was carried out as described (Lee et al., 2000; Okabe et al., 1996) with 
modifications. 
 
2.4.1. Cultivation and preparation methods 
 NSC were cultured in our lab right after isolation from the embryonic striatal tissue 
(P1). After thawing and resuspending in Dulbecco´s Modified Eagle Medium (Gibco) 
supplemented with F-12 (Gibco), B-27 (Gibco), 1M HEPES (SIGMA), 200mM Glutamine 
(Gibco), 0,6% Glucose, EGF and bFGF (both at 10 ng/ml; SIGMA),  the cells were cultured in 
uncoated culture flasks (25 cm2). After 3-4 days, the formation of neurospheres (Fig. 2.4) 
was observed and after about 7 days the cells located in the centre of the spheres began to 
change their colour, started to become necrotic and died. For passaging, cultures were then 
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centrifuged, spheres were mechanically dissociated and cells were resuspended in culture 
medium at a density of 50,000 cells/ml.  
Prior to transplantation neurospheres from the third to sixth passage were collected in Hank’s 
balanced salt solution (PAA) 3-4 days after the last passage and either mechanically 
dissociated or left as intact spheres. In order to obtain equal concentrations of cells in both 
graft preparations, I counted the viable cells in an aliquot of both, dissociated cells and 
neurospheres. The graft suspensions were then diluted to a concentration of 20,000 cells/µl 
and placed on ice until transplantation. 
 
 
Figure 2.4. EGFP+ Neurospheres in vitro 
Photograph of two neurospheres after four days 
in vitro. NSCs grow free floating in a suspension 
culture. They expand in a concentric manner 
and form so called neurospheres. 
 
  100 µm 
 
 
 
ENSCs were sent to us from our collaborators in Hamburg after predifferentiation to 
Nestin+ cells. In our tissue culture lab cells were then thawed and resuspended in Dulbecco´s 
Modified Eagle Medium (Gibco) supplemented with F-12 (Gibco), B-27 (Gibco), 200mM 
Glutamine (Gibco) and bFGF (10 ng/ml; SIGMA) and plated out into Poly-L-Ornithin (PLO; 
200µg/ml; SIGMA) and Laminin (1µg/ml; Roche)-coated culture flasks (25 cm2). When the 
cells reached confluency they were passaged and plated out into PLO- and Laminin-coated 
flasks (75 cm2). For passaging, cells were incubated with Trypsin (Gibco) until they dissolved 
from the surface and resuspended in culture medium at a density of 50,000 cells/ml. 
 
2.4.2. In vitro differentiation 
 In order to test the differentiation potential of NSCs and make sure that the cells are 
able to differentiate in vitro as described elsewhere, I differentiated the cells according to the 
following in vitro protocol: 
Glass coverslips were put into each well of a 24-well plastic plate and coated with Poly-L-
Lysin (PLL; 200µg/ml; SIGMA). Neurospheres from the third to eighth passage were 
resuspended in culture medium at a density of about 200,000 cells/ml. 500 µl of the cell 
suspension was poured into each well and placed in the incubator to allow spheres to adhere 
to the surface. After 24 hours, the culture medium was withdrawn and replaced by 
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differentiation medium (culture medium without the growth factors EGF and bFGF). Three to 
seven days later, cells were processed for immuncytochemical staining. 
 
2.4.3. Immuncytochemistry 
 The in vitro differentiation of the stem cells to the three different CNS cell types: 
neuron, astrocyte and oligodendrocyte was evaluated by immunofluorescence staining using 
primary antibodies that bind to cell specific antigens. All stainings were performed using two 
different primary antibodies and two corresponding fluorescence-conjugated secondary 
antibodies. The advantage of this method is the use of two different cell markers in one 
protocol for the same cells. The antibodies used in parallel came from different species, i.e. 
rabbit and mouse, so that the specific binding of the two different secondary antibodies was 
given. To boost the EGFP signal of the stem cells, I always performed double 
immunofluorescence staining using a rabbit anti-EGFP antibody in combination with different 
anti-mouse antibodies. All antibodies used for this method are listed in Tab. 2.4. 
Prior to the double immunofluorescence staining, culture medium was removed and cells 
were washed three times with PBS (0.1 M pH 7.4). After that cells were fixed with 4% 
paraform aldehyde (PFA) for 30 min at room temperature (RT). 
Staining procedure was then performed using the following protocol (all steps were 
performed at RT except where stated otherwise): 
 
• Washing (PBS), 3 X 5 min 
• Blocking of unspecific binding sites [3% normal goat serum and 1% Triton X-
100 in Antibodydiluent (PBS containing 1% bovine serum albumine)], 1h 
• Incubation with the primary antibodies (1%  Triton X-100 in Antibodydiluent; 
antibody working dilutions are listed in the Tab. 2.4), over night, moist 
• Washing (PBS), 3 X 5 min 
• Incubation with the secondary antibodies (Antibodydiluent; antibody dilutions 
are listed in Tab. 2.4), 3h, dark, moist 
• Washing (PBS), 3 x 5 min, dark 
• Incubation with the nuclei marker DAPI (Antibodydiluent, 1:1000), 5 min, dark 
• Washing (PBS), 3 x 5 min, dark 
 
After the last washing, PBS is withdrawn from the wells and the glass coverslips are carefully 
removed and put onto object slides. Mounting was performed using Immunofluor Mounting 
Medium (MP Biomedicals; Eschwege, Deutschland). 
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Table 2.4. Antibodies used for Immuncytochemistry (IC) and Immunhistochemsitry                          
                 (IHC) 
 
Antibody Manufacturer, 
catalogue no. 
Working dilution, 
IC 
Working dilution, 
IHC 
Cell type 
ßTubulinIII SIGMA, T8660 1:200 1:200 Neuron 
CD11b (Integrin 
α M) clone 5C6 
Chemicon,      
MAB 1458 
/ 1:2500 Microglia 
CNPase SIGMA, C5922 1:500 1:500 Oligodendrocyte 
DARPP-32 Chemicon, 
AB1656 
/ 1:5000 Striatal projection 
neurons 
pEGFP (rabbit 
anti-mouse) 
Chemicon, 
AB16901 
1:1000 1:1000 NSC (EGFP+) 
pEGFP (chick 
anti-mouse) 
Chemicon, 
AB 16901 
/ 1:1000 NSC (EGFP+) 
pGFAP DAKO, Z 0334 1:5000 1:2000 Astrocyte 
mGFAP SIGMA, N 5389 1:1000 1:1000 Astrocyte 
MAP-2a/b clone 
AP-20 
SIGMA,  
M 1406 
1:250 1:250 Neuron 
NeuN Chemicon, 
MAB377 
1:200 1:100 Neuron 
Nestin Chemicon, 
MAB353 
1:1000 1:500 undifferentiated 
NSC 
pNG-2 Chemicon, 
AB5320 
/ 1:500 Oligodendroglial 
precursors 
AlexaFluor488 
Goat Anti-Rabbit 
IgG 
Molecular 
Probes, 
A-11008 
1:1000 1:500-1:1000 / 
AlexaFluor488 
Goat Anti-Chick 
IgG 
Molecular 
Probes, 
A-11039 
/ 1:1000 / 
AlexaFluor594 
Goat Anti-Mouse 
IgG 
Molecular 
Probes, 
A-11032 
1:1000 1:500-1:1000 / 
Biotin 
conjugated Goat 
anti-rabbit IgG 
Vector,  
BA-1000 
/ 1:500 / 
Biotin 
conjugated Goat 
anti-mouse IgG 
Vector,  
BA-2000 
/ 1:500 / 
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2.5. Histology 
 
2.5.1. Preparation of tissue 
At the time of sacrifice, animals were killed by overdose of isofluoran and received 
transcardial perfusion with 0.9% NaCl and 4% paraformaldehyde in 0.1M PBS (pH 7.4). After 
decapitation and dissection, the brains were post fixed for 2h in 4% paraformaldehyde in 
0.1M PBS (pH 7.4), followed by immersion 48h at 4°C in 30% sucrose. The brains were then 
shock frozen in -50°C cooled isopentane and stored at -80°C before cutting on a cryostat. 
 
2.5.2. Immunhistochemistry 
Coronal sections (30µm thick) were collected in PBS and processed for 
immunhistochemical staining following a free floating protocol and processed for either 
Diaminobenzidine (DAB)-staining or fluorescent staining at RT. 
  
DAB-staining: 
• Sections were carefully transferred to small baskets set into a 24-well plate filled with 
PBS 
• Blocking of endogenous peroxidase activity (3% H2O2 in PBS), 10 min 
• Washing (PBS), 3 X 5 min 
• Blocking of unspecific binding sites (1% Triton X-100 and 3 % normal goat serum in 
Antibodydiluent), 1h, shaker 
• Incubation with the primary antibody (1% Triton X-100 in Antibodydiluent; antibody 
working dilutions are listed in Tab.2.4), over night, shaker 
• Washing (PBS), 3 X 5 min 
• Incubation with secondary antibody (1% Triton X-100 in Antibodydiluent; antibody 
working dilutions are listed in Tab.2.4), 1h  
• Washing (PBS), 3 X 5 min 
• Incubation with avidin-biotin-peroxidase complex (Vector) in PBS, 1h, shaker 
• Washing (PBS), 3 X 5 min 
• Chromogen reaction [100 mM NiSO4; 125 mM sodium acetate; 10 mM imidazole; 
0.03% 3,3-diaminobenzidine (DAB); 0.003% H2O2, pH 6.5] 
• Washing (PBS), 3 X 5 min 
• Sections were mounted on SuperFrost object slides and dried for at least 30 min 
 
After the DAB-staining all slides were processed for Thionin staining to mark the nuclei of 
every cell and show the architecture of the whole tissue. 
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• Incubation in distilled water for 1 min 
• Incubation in Thionin (0.02% in distilled water with acetic acid and NaOH) for 1-2 min 
• Washing in distilled water 2 X 15 sec 
• Dehydration in increasing alcohol solutions (50%, 70%, 96%, 100% EtOH), 
incubation for 30 sec each 
• Incubation in 100% Xylol  2 X 1 min 
• Mounting with DPX 
 
After mounting, object slides were stored under dry conditions at RT. 
 
Fluorescent staining: 
• Sections were carefully transferred to small baskets set into a 24-well plate filled with 
PBS 
• Washing (PBS), 3 X 5 min 
• Blocking of unspecific binding sites (1% Triton X-100 and 3 % normal goat serum in 
Antibodydiluent), 1h, shaker 
• Incubation with the primary antibodies (1% Triton X-100 in Antibodydiluent; antibody 
working dilutions are listed in Tab.2.4), over night, shaker 
• Washing (PBS), 3 X 5 min 
• Incubation with secondary fluorescent-conjugated antibodies (1% Triton X-100 in 
Antibodydiluent; antibody working dilutions are listed in Tab.2.4), 3h  
• Washing (PBS), 3 X 5 min 
• Incubation with the nuclei marker DAPI (Calbiochem; Antibodydiluent, 1:1000), 5 min, 
dark 
• Washing (PBS), 3 x 5 min, dark 
 
Mounting was performed using Immunofluor Mounting Medium (MP Biomedicals; Eschwege, 
Deutschland). Object slides were sealed with nail-varnish to avoid dehydration and stored 
under dry and dark conditions in the cold room (4°C). 
 
2.5.3. Analysis 
Microscopy and measurement of lesion- and graft volume 
The lesion volume was calculated by measuring the non-stained part of the striatum 
and the whole striatal area in photomicrographs of DARPP-32 stained sections. The lesion 
size was defined as the percentage of striatal area that was non-stained in sections 
processed for DARPP-32 immunoreactivity. For each striatum a mean of 4 slices located 
anterior, posterior and in the middle of the lesion were measured. Absolute volumes of the 
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grafts were estimated as described by Cavalieri: To evaluate the graft volume, 
photomicrographs were made from every third section throughout the graft. The area of the 
graft (mm2) was measured in each photomicrograph (Ai) in a blinded manner and multiplied 
by 3 (every third section measured) and then multiplied by 0.03 mm (thickness of sections) to 
get the partial volume (Vi=Ai*3*0.03 mm) represented by each photograph. The total graft 
volume (mm3) was defined as the sum of the calculated partial volumes (V=∑Vi). To verify 
similar cell densities in the grafts, cell counts were performed in 3 animals of each 
experimental group. Cell density was measured in 2 different sections each. Photographs 
(X40) were made from each section and analysed with Photoshop (Adobe) as follows: A 
square of 59,000 µm2 was marked inside the area of the grafted cells. All EGFP+-cells were 
counted and the cell density was estimated [cells X 105/mm3]. For each group, 3 animals 
were analysed and a mean value was calculated. 
 
Microscopy and measurement of GFAP- and CD11b-staining 
Relative immunoreactivity of GFAP- and CD11b-stainings was estimated to quantify 
the increasing glial reaction of astrocytes (GFAP) and microglia (CD11b). For each survival 
time after QA-lesion, at least two animals were examined in a blinded manner. Three 
sections of each animal were measured as follows: In every section the lesioned and 
unlesioned striatum was photographed and the grey value was measured with Image I (NIH). 
The value of the lesioned side was devided by the value of the unlesioned side, so that 
intensity is expressed relative to background staining. 
 
Confocal laser microscopy 
Confocal laser microscopy was performed with help of the according software (Leica 
DMR). An Argon/Krypton laser was used with the folloeing excitation wavelengths: 488 nm 
for the green fluorescence and 546 nm for the red fluorescence. For each photograph, a z-
scan over 20 to 25 sections (about 1 µm) was performed and single layers were projected to 
one picture. 
 
 
2.6. Behavioural tests 
After transplantation of eNSCs into QA-lesioned animals we tested the functional 
improvement of the mice by testing behavioural skills. Each mouse was subjected to two 
different behavioural tests during the 3 months after QA-lesion and cell transplantation: First, 
the Limb-use asymmetry (cylinder) test was conducted preinjury (only in case of the QA-
lesioned and PBS control animals) and 1, 4, 8 and 12 weeks after QA-lesion and cell-
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transplantation. Second the drug induced rotation behaviour was tested 1, 4, 8 and 12 weeks 
after QA-lesion and cell transplantation. 
All behavioral tests were performed at the beginning of the animals´ dark phase. 
 
2.6.2. Cylinder test  
This behavioural task, designed for rats by Schallert et al (Fig. 2.6.1), was used to 
analyze the asymmetry of the limb-use of mice after QA lesion. The animals were placed into 
a glass cylinder that was wide enough to allow movement but small enough to encourage 
rearing and wall exploration (diameter 10 cm). The height of the cylinder impeded the mouse 
from reaching the top edge (height 30 cm). Independent versus combined use of the 
forelimbs during vertical exploration of the walls was scored by observing the mouse and 
counting every forelimb placement until a sum of 30 movements were performed. Percent-
use scores were calculated for (1) movements using the non-impaired limb relative to the 
total number of movements and (2) movements using the impaired forelimb relative to the 
total number of movements. The percent use of the impaired limb was then subtracted from 
the percent use of the unimpaired limb to create an overall limb-bias score. Average scores 
for each week of testing (2 sessions per week) were calculated for each animal (Roof et al., 
2000). 
 
Figure 2.6.1. Cylinder test 
Photograph showing the original 
cylinder designed for rats. The 
animal is placed inside and has 
enough space for rearing and wall 
exploration, which can be easily 
observed through the plastic or 
glass material of the cylinder. 
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2.6.1. Drug-induced rotation behaviour 
The drug-induced rotation behaviour is a very common behavioural test performed 
after unilateral lesion of the basal ganglia. After the application of Amphetamine, the 
imbalance of basal ganglia activity leads to an enhanced activation of the motor functions 
contralateral to the lesion side. About 5 minutes after the application of Amphetamine, mice 
show a rotation movement in the direction ipsilateral to their lesioned hemisphere. Rotation 
was measured in a bank of automated rotometer bowls (Accuscan Instruments, USA) where 
mice were fixed with an elastic around their body (Fig. 2.6.2). Mice were tested for rotation in 
response to injection of 5 mg/kg IP d-amphetamine sulphate in sterile water. All mice were 
tested 1, 4, 8 and 12 weeks after transplantation surgery and tests were conducted over 30 
min, respectively. (Fricker et al., 1996). 
Percent of right turns were calculated for the number of right turns relative to the total 
number of turns (rotational bias). All tests were performed in a blinded manner. 
 
Figure 2.6.2. Drug-induced 
rotation behaviour 
Photograph of one of the 
commercially available auto-
mated rotometer bowls from 
Accuscan, USA. The animal is 
placed into the cylinder after it 
was fixed with an elastic tie 
around its body. The fixation is 
connected to the cover of the 
cylinder. 
 
 
 
 
 
 
2.7. Western blotting 
In order to investigate BDNF protein expression after excitotoxic lesion, we prepared 
protein lysates from both striata of unilaterally lesioned mice (n = 11) 2, 7 and 14 dpo. At 
each date after lesion, hemispheres were split and the striata were prepared and weighed 
separately. Tissue was homogenized by a sonicator in HEPES buffer (20 mM HEPES, pH 
7.4) containing a cocktail of proteinase inhibitors (1:200, SIGMA). After centrifugation at 
13,000 rpm for 15 min at 4°C, supernatants were removed and frozen at –20°C.Lysate 
samples, normalized for protein content, were boiled for 3 min in NuPAGE® LDS sample 
buffer (Invitrogen) containing 0.5 µl DTT. Proteins were separated with SDS-PAGE in 4-12% 
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Tris-Bis NuPAGE® polyacrylamide gels (Invitrogen) at 100 V at room temperature, then 
transferred overnight at 4 °C onto nitrocellulose (tank blotting, NuPage® transfer buffer 
containing 20% methanol; Invitrogen). To confirm that equal amounts of protein were 
transferred from each sample, membranes were stained with 0.15% Ponceau S in destilled 
water. After Ponceau S staining, membranes were blocked for 1 h in 5% BSA in Tris-buffered 
Saline plus 0.1% Tween 20 (TBST, pH 7.4) at room temperature, followed by incubation in 
primary antibody against BDNF (1:1000; rabbit polyclonal, Santa Cruz Biotechnology, Santa 
Cruz, CA) diluted in TBST containing 1% normal goat serum (Amersham) at 4°C, overnight. 
After washing, the membrane was incubated 1 h at room temperature with HRP-conjugated 
goat anti-rabbit antibody (1/2000, Pierce). 
Bands were visualized using the “Super Signal West Femto” chemiluminescence kit (Pierce) 
according to the manufactor´s instructions. Relative protein concentrations were quantified 
by comparing optical densities of protein bands using a digital image analysis system (LTF). 
 
 
2.8. Statistics 
To test the influence of graft preparation and time of transplantation on the survival of 
the graft, we performed two-way-ANOVA and Bonferroni-corrected t-tests by means of a 
statistic software package (GraphPad Prism, Version 4.02). Lesion size, relative 
immunoreactivity of GFAP and CD11b and the results of the behavioural tests were also 
tested by one-way-ANOVA by means of the statistic software JMP (Version: 4.0.0, SAS 
Institute Inc.) and Student’s post hoc test. 
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3. Results 
 
 
3.1. Time of transplantation and cell preparation determine neural stem cell survival in 
a mouse model of Huntington’s disease 
 
 
 
3.1.1. Introduction 
Cell replacement therapies for neurodegenerative diseases, using multipotent neural 
stem cells, require above all a good survival of the graft and therefore an understanding of 
the possible influence of the surrounding degenerating tissue on the grafted cells. In the 
following study, we unilaterally injected quinolinic acid (QA) into the striatum of adult mice 
and transplanted syngeneic neural stem cells of enhanced green fluorescent protein (EGFP)-
transgenic mice into the lesioned striatum. The injection of QA leads to an excitotoxic lesion 
with selective cell death of the medium sized spiny neurons, the same cells that are affected 
in Huntington´s disease. Since the glial cells react very strongly to the excitotoxic lesion, we 
examined both, astrocyte and microglia activation at the site of transplantation, assuming an 
influence of activated glia on graft survival. In order to investigate the best timing of 
transplantation for the survival of donor cells, we transplanted the stem cells at 2, 7 and 14 
days after injury. In addition, the influence of graft preparation prior to transplantation (i.e. 
intact neurospheres vs. dissociated cell suspension) on graft survival was investigated. 
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3.1.2. Lesion size 
Since the excitotoxic lesion model has not yet been characterized well in mice, we 
established the stereotactic coordinates (see chapter 2.3.1) for the defined injection of QA 
that leads to an overall striatal lesion due to the loss of DARPP-32+-projection neurons in 
about 70% of the striatum. In the centre sections of the lesion almost 100% of the DARPP-
32+-neurons are lost. The size of the lesion could be easily identified after DARPP-32-
staining (Fig. 3.1.1).  
 
 
 
b 
 
 
 
 
 
 
a 
Figure 3.1.1. Striatal lesion after injection of quinolinic acid 
Photomicrographs (x25 objective) of immunhistochemically stained cryosections after 
intrastriatal PBS- (a) and QA- (b) injection. The QA-lesioned striatum shows the 
centre of the lesion, where almost 100% of DARPP-32+cells have died. DAB-staining 
was performed using pDARPP-32 antibody. 
 
 
In the experimental approach of transplanting NSCs at different time points after QA-
injection, we quantified the lesion size of all animals applying DARPP-32 immunhisto-
chemistry. A mean value was calculated for each experimental group of animals (Tab. 3.1.1) 
and there was no significant difference in lesion size between all groups. 
 
 
 
Table 3.1.1. Size of striatal lesion (mean +/- SEM) after QA injection measured 
by loss of DARRP-32 staining 
 2 dpo 7 dpo 14 dpo 
Neurospheres 66.36 +/- 10.09% (n=6) 77.89 +/- 3.17% (n=4) 66.04 +/- 8.30% (n=4)
Single cells 73.59 +/- 4.66% (n=8) 72.34 +/- 3.20% (n=9) 59.33 +/- 7.57% (n=8)
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3.1.3. In vitro differentiation of NSCs 
 In order to test the differentiation potential of the NSCs, I cultured the cells in PLL-
coated flasks and removed the growth factors from the culture media to initiate 
differentiation. After double-immunofluorescent staining with different cell markers, I was able 
to identify cells which express markers forneurons, astrocytes, oligodendrocytes and 
undifferentiated NSCs (Fig. 3.1.2). Every cell marker tested was expressed in some of the 
differentiated cells. I estimated the proportion of neuronal, astroglial and oligodendroglial 
differentiation and found that neuronal markers such as NeuN and MAP-2 could be identified 
in about 5-10% of the differentiated cells. The expression of the oligogendroglial marker was 
only occasionally detected: about 1% of the NSCs were double-labelled with CNPase. Most 
of the cells expressed the astroglial marker GFAP (about 50%) and Nestin (about 40%), 
which is a marker for undifferentiated NSCs. The differentiation potential of the NSCs could 
be influenced with retinoic acid (RA), different growth factors and cytokines, such as ciliary 
neurotrophic factor (CNTF). In preliminary data, I found out that retinoic acid and CNTF 
enhanced the neuronal differentiation potential of the stem cells. The increase of neuronal 
differentiation after RA-treatment or CNTF-treatment was about 100%. However, since the 
initial neuronal differentiation was only 5-10%, the amount of neurons after the treatment was 
only about 20%, which is still far too less to be considered as an effective pre-differentiation 
method. Since I had to focus on the transplantation studies, I decided not to go on with the in 
vitro differentiation experiments. It was though very important to demonstrate that the cells 
are able to express neuronal, astrocytic and oligodendrocytic cell markers. Additionally, I 
observed that the EGFP-expression of the NSCs decreased in parallel with increasing 
differentiation in vitro and that almost 50% of the cells could hardly be detected by their 
green fluorescence. This observation is important for the further results and will be discussed 
later. 
 
 
  
 
Figure 3.1.2. Immuncytochemistry of in vitro differentiated NSCs 
Photomicrographs (a - c: X20 objective, d – o: X40 objective) show in vitro differentiated 
NSCs 4 days after growth factors were withdrawn from the culture media. 
a – c) EGFP+-cells double-labelled with DAPI and NeuN, a nuclei marker for neurons; d – f) 
EGFP+-cells double-labelled with DAPI and MAP-2, which stains the cytoplasm of neurons; g 
– i) Astrocytic differentiation is shown by double-labelling of EGFP+-cells with DAPI and 
GFAP; j – l) Double-labelling of EGFP+-cells with DAPI and CNPase shows a 
morphologically mature oligodendrocyte; m – o) undifferentiated NSC or radial glia are 
stained by the Nestin-antibody which is also used in a double-labelling protocol with DAPI. 
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3.1.4. Graft survival of NSC after transplantation into excitotoxically lesioned striatum 
Neural stem cells grow as neurospheres in vitro (Fig. 2.4) and can be transplanted as 
intact spheres or as single cell suspensions. We compared both of the donor cell preparation 
methods to assess their influence on graft survival. Since only very few cells were found 
apart from the graft core, which displayed a very similar morphology in each experimental 
group, we decided to quantify the survival of the grafted cells by measuring the volume of the 
graft cores. Cell density in the grafts were also quantified to make sure that the differences in 
graft volume only were due to differences in surviving cells and not an artefact of varying cell 
densities. As shown in Fig. 3.1.3d – i the cell density was very similar in each experimental 
group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1.3. Graft volume and density 
a - c) Photomicrographs (X5 objective) show grafted neurospheres in 2 dpo (a), 7 dpo (b) 
and 14 dpo (c) transplanted animals. EGFP+-cells are green and DAPI-stained nuclei are 
blue. All grafts are located in the lesioned striatum 14 days after transplantation. Scale bar: 
500µm. 
d - i) Photomicrographs with higher resolution (X10 objective) of grafted neurospheres (d – 
f) and single cells (g –i) at each transplantation date. Scale bar for d-i: 100µm. 
 
27 
When quantified, the cell density was about 105 cells/mm3 in each group without a 
significant difference (Fig. 3.1.4b). When graft volumes were quantified two weeks after 
transplantation, we found that transplanted neurospheres demonstrated better survival than 
single cell suspensions, regardless of the timing after QA lesioning of the striatum (Fig. 
3.1.4a). Control animals (without a striatal lesion) also received grafts of both types of NSC 
preparation (i.e. single cells and neurospheres) and again, 14 days after transplantation, 
neurospheres demonstrated better survival (graft volume of single cell suspension: 0.017 
mm3, neurospheres: 0.074 mm3). 
Furthermore, we tested the influence of the time gap between excitotoxic lesion and time of 
transplantation on the survival of the grafts. Single cell suspensions or intact neurospheres 
were transplanted into the striata of excitotoxic lesioned mice 2, 7 and 14 days post QA 
injection (dpo). The survival of both types of NSC preparation was improved when 
transplantation took place shortly after QA lesioning. Graft volumes of transplanted 
neurospheres (0.184 +/- 0.066 mm3) and single cell suspensions (0.059 +/- 0.020 mm3) at 2 
days after lesion were larger than those transplanted either 7 or 14 days after lesion (7 dpo: 
single cells 0.025 +/- 0.004 mm3, neurospheres 0.042 +/- 0.012 mm3 and 14 dpo: single cells 
0.024 +/- 0.005 mm3, neurospheres 0.035 +/- 0.009, respectively).  
By far the best survival of the NSC graft was observed when neurospheres were 
transplanted early after QA lesion. The graft volume measured in the animals transplanted 
with neurospheres 2 dpo was 4 fold increased in comparison to the other groups (Fig 3.1.3a 
and Fig. 3.1.4a). Two-way ANOVA showed a significant influence of both parameters, graft 
preparation (p<0,001) and transplantation timing (p<0.01) as well as a significant interaction 
of the parameters (p<0.05). The sources of variation were first the transplantation timing 
(F=12,38), secondly the graft preparation (F=8.93) and thirdly the interaction (F=4.71). 
Bonferroni-corrected t-tests demonstrated a highly significant difference of the graft volume 
of neurospheres transplanted 2 dpo to the graft volume of single cells 2 dpo (p<0,01). 
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Figure 3.1.4. Graft survival depends on graft preparation and date of 
transplantation. 
a) Mean value of the graft volume [mm3] measured in transplanted animals 2, 7 or 14 
days after QA-lesion, following a survival period of 14 days. Columns demonstrate 
grafted neurospheres (gray, n=3 animals) and single cell suspensions (black, n=6). Error 
bars show standard error of the mean, SEM. Asterisks indicate highly significant 
difference between single cell and neurosphere transplantation at 2 dpo (p< 0.01).  
b) Mean value of the graft density [cells x 105/mm3] measured 2, 7 and 14 days after QA-
lesion and 14 days survival. Columns demonstrate grafted neurospheres (gray, n=3) and 
single cell suspensions (black, n=6). Error bars show SEM. There was no significant 
difference between the groups. 
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3.1.5. Astroglia- and microglia activation in the striatum after injection of quinolinic acid 
To better understand the environmental conditions that can affect the grafted cells, 
we investigated the glial reaction at 2, 7 and 14 days after QA injection. Immunhistochemical 
stainings of GFAP and CD11b were performed to reveal astrogliosis and microglia activation, 
respectively. At 2 dpo, both microglia activation and astrogliosis were moderate. However, 
the changes at the later survival times were more striking. At 7 and 14 dpo the lesioned 
striatum contained many glial cells with changed morphology. Two days after QA injection, 
mainly round cells were found in the CD11b-stained striata, while 7 and 14 days after lesion, 
microglia had proliferated massively and displayed hypertrophic processes (Fig. 3.1.5g, h). 
The astrocytes show a similar pattern: early after lesion, some activated astrocytes appeared 
in the lesioned striatum which had a similar morphology as the ones in the contralateral 
hemisphere. Seven days after surgery, the lesioned striatum was filled with GFAP+-cells that 
displayed a denser morphology with thicker but shorter processes (Fig 3.1.5c). This 
morphology was also apparent in the striatum at 14 days after lesion, where astocytes 
started to build a network of dense processes (Fig. 3.1.5d). We also quantified these 
observations by measuring the relative immunoreactivity (IR) and found a significant increase 
of both GFAP- and CD11b-IR at 7 dpo and 14 dpo (7dpo: rel. GFAP-IR=1,162, rel. CD11b-
IR=1,262; 14 dpo: rel. GFAP-IR=1,104, rel. CD11b-IR=1.268) as compared to the relative IR 
at 2 dpo (rel. GFAP-IR=0.868, rel. CD11b-IR=0.866). 
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Figure 3.1.5. Increasing astrogliosis and activation of microglia after excitotoxic 
striatal lesion  
a - h) Glial activation after intrastriatal QA injection. Photomicrographs of GFAP stained 
astrocytes (a-d) demonstrate increasing astrogliosis with a moderate astroglia activation 
at 2 dpo (b), a more complex network of astrocytes at 7dpo (c), and formation of a glial 
scar at 14 dpo (d). Staining of CD11b (e-h) shows the increasing microglia activation at 2 
dpo (f), 7 dpo (g) and 14 dpo (h). Control experiments (a, e) show the contralateral 
hemisphere at 2dpo. Scale bar: 20µm. i) Mean value of the relative GFAP- and CD11b-
immunoreactivity in QA-lesioned mice at 2, 7 and 14 dpo. Values of indirect 
immunostaining with HRP-labelled antibodies and DAB reaction were measured 
photometrically. Each column represents three different sections of one animal. Error 
bars show standard SEM. The experiment was repeated once with a similar result. 
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3.1.6. BDNF protein expression remains almost constant until 14 days after QA injection 
Because of the dramatic cellular changes in the striatum after QA lesion, we were 
also interested in accompanying molecular changes that may account for differences in 
survival of the grafts. We investigated the relative immunreactivity of BDNF. In the animals 
sacrificed 2 and 7 days after QA-lesion, the BDNF-level of the lesioned striatum did not 
change when compared to the unlesioned contraleral hemisphere, although there was a high 
variability between the probes at 2 dpo. At 14 dpo the BDNF-immunreactivity of the lesioned 
striata was reduced by about 10% in comparison to that of the contralateral, non-lesioned 
striata, but this was not significant. This finding demonstrates that despite the dramatic 
cellular changes that took place after QA injection into the striatum, there was no significant 
change in the relative BDNF concentration in the striatum (Fig. 3.1.6). 
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Figure 3.1.6. BDNF protein level in the 
striatum does not change until 14 days 
after QA lesion 
a) Chemiluminescence using an anti-
BDNF antibody on purified human BDNF 
protein (hBNDF) and tissue from the 
striatum of QA-lesioned animals sacrificed 
2 days post operation (dpo), 7 dpo and 14 
dpo shows the mature form of BDNF 
protein at 14 kDa. For each date after 
lesion, hemispheres were split and 
separate protein lysates of the lesioned (l) 
and the contralateral (c) striatum were 
obtained. b) Histogram of average BDNF 
levels in the lesioned striata (expressed as 
a percentage of the contralateral BDNF 
level +/- SEM; n=5) show that the BDNF 
level remained constant. 
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3.1.7. Long term graft survival and differentiation of neurosphere grafts transplanted 2 dpo 
As shown above, NSC neurosphere grafts survived best when transplanted early 
after excitotoxic lesion. We next examined the long-term survival and differentiation potential 
of these grafts transplanted 2 dpo. 
The NSC grafts could still be detected three months after transplantation where a mean graft 
volume of 0.056 +/- 0.017 mm3 was estimated. Since the measured graft volume is much 
less than in the animals that were sacrificed 14 days after transplantation, we assumed that 
some of the grafted cells died in between. The graft morphology was also slightly different 
from that after 14 days of survival: The cells seemed to be more separated and several cells 
displayed a very distinct morphology (Fig. 3.1.7d). Although these morphologies were similar 
to the ones of differentiated neuons and oligodendrocytes, double-immunofluorescence for 
neuronal (NeuN, Fig. 3.1.7a - c) and oligodendroglial (NG-2 and CNPase, Fig. 3.1.7d - i) 
markers demonstrated a lack of these markers. Most of the grafted cells expressed the 
astroglial marker (GFAP; Fig. 3.1.7j - l) and therefore can be seen as differentiated 
astrocytes or astrocyte progenitors. Furthermore, none of the donor cells did express nestin, 
a marker for undifferentiated NSC as well as the microglial marker CD11b (data not shown). 
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Figure 3.1.7. In vivo differentiation three months after transplantation 2 dpo 
Confocal laser microscope analysis of double-stained striatal sections of an animal 
transplanted 2 days after QA-lesion and sacrificed three months after transplantation. EGFP 
signal was enhanced by green immunofluorescence staining against EGFP (a, d and g). 
Serial sections were processed for red immunofluorescence staining against NeuN (b), 
CNPase (e), NG-2 (h) and GFAP (k). Overlays of the single signals show double-labelling 
only after EGFP/ GFAP-double-staining (l): Almost all of the grafted cells express GFAP. 
Scale bar = 80 µm.  
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3.2. Transplantation of NSC into the striatum of HD transgenic mice 
 
 
 
3.2.1. Introduction 
 Unlike the QA-model, which can be seen as a very static Huntington´s disease model 
and represents more the later phase of the disease, the transgenic R6/2 mouse is a 
progressive disease model. The inserted nucleotides represent the Exon 1 of the human 
Huntingtin-gene which includes a mutant enlarged CAG-repeat that leads to a polyglutamine-
tract in the huntingtin protein fragment. 
Because the transgene is expressed stably and constitutively, the mice show a progressive 
neurological phenotype which is similar to that of HD patients. Also some neuropathological 
features like brain atrophy and the formation of so called neuronal inclusions which are 
formed mainly by aggregated polyglutamines, can be observed in the transgenic mouse 
model (Davies et al., 1998). Astrocytic activation is moderate in the striatum of these mice 
and only progresses very slowly. 
Since the glial reactions after QA-lesion seem to limit graft survival and migration after NSC-
transplantation into the excitotoxic lesioned mice, I wanted to investigate the appearance and 
graft morphology as well as the differentiation potential of NSCs after transplantation into the 
R6/2 transgenic mouse model, expecting that the difference of the host tissue physiology 
might result in a different graft physiology. 
Neurospheres were transplanted into the striatum of 8 week old transgenic mice as 
described in chapter 2.3.2 and all animals were sacrificed after 3-4 weeks of survival. 
Preparation of the tissue and immunhistochemical processing was performed as described in 
chapter 2.5. 
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3.2.2. Graft morphology and location in the host tissue 
 Transplantation of NSCs as a neurosphere suspension into the striatum of R 6/2 HD 
transgenic mice resulted in a better migration of the cells in the host tissue when compared 
to the same grafts in QA-lesioned wt mice. Although the survival time after transplantation 
was only 3-4 weeks, the grafted cells seemed to develop a more distinct morphology and 
more single cells could be found apart from the graft core (Fig. 3.2.1.c). Furthermore, there 
were several cells that had established long processes, especially those lying in the corpus 
callosum of the host (Fig. 3.2.1.a-b). Most interestingly, I found very few cells that displayed 
a very pronounced oligodendroglial morphology (Fig. 3.2.1.d).  
 
 
 
 
Figure 3.2.1. Graft morphology 
Photomicrographs of NSC grafts transplanted into 
HD transgenic mice.  
a) Grafted neurospheres are more distributed in 
the tissue and show a certain affinity to the white 
matter (corpus callosum). 
b) The graft shows different morphological parts. 
In some areas, mostly in the corpus callosum, 
there are long processes which seem to follow the 
orientation of the corpus callosum (arrow).  
c) More cells are apart from the graft core and lie 
separated in the host parenchyma. The 
morphology of the cells is different: some cells 
display a more astrocytic morphology (arrow) 
while others have dense processes that seem to 
be strictly oriented (arrowhead). 
d) High magnification of a transplanted NSC. The 
morphology displays a cell soma with highly 
orientated processes. This kind of cell has strong 
similarity with an oligodendrocyte. 
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3.2.3. In vivo Differentiation 
 In order to investigate whether these pronounced morphologies of the grafted cells 
were due to an in vivo differentiation to certain cell types, I processed a series of sections for 
immunhistochemical double-labelling with cell markers for all cell types of the CNS (Fig. 
3.2.2). After confocal laser microscopic analysis, I could detect a lot of GFAP+-cells, which 
was very similar to the results of the NSC transplantations in the QA-lesioned animals. 
Additional to these cells, I also found grafted cells that were double-labelled with NG-2, a 
marker for oligodendroglial precursors. Especially the stellar shaped cells, that were placed 
somewhat apart from the graft core, where double-labelled with the main colocalization 
appearing in the cell somata (Fig. 3.2.2o). Because of the oligodendroglial-like morphology 
shown in Figure 3.2.1d, I was trying hard to detect cells of this shape double-lablelled with 
the oligodendroglial marker CNPase. But although I found cells with a lot of processes 
ending in the white matter of the typical striatal bundles where a lot of oligodendrocytes 
ensheath the ascending and descending axons, they were not double-labelled with CNPase 
and therefore cannot be seen as differentiated oligodendrocytes (Fig. 3.2.2i). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.2. In vivo differentiation of NSC grafts in HD tg mice 
Confocal laser microscopic analysis of double-stained striatal sections of two tg animals 
transplanted with a neurosphere-suspension and sacrificed four weeks after transplantation. 
EGFP signal was enhanced by green immunofluorescence staining against EGFP (a, d, g, j 
and m). Serial sections were processed for red immunofluorescence staining against NeuN 
(b), MAP-2 (e), CNPase (h), GFAP (k) and NG-2 (n). Overlays of the single signals show 
double-labelling only after combining EGFP with GFAP and NG-2 staining (l, o). Most of the 
grafted cells express GFAP and some cells express the oligodenrdocyte-precursor marker 
NG-2, which also shown in the inlay photograph at a higher magnification (o, scale bar = 8 
µm). 
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3.3. Neural cell adhesion molecule L1-transfected embryonic stem cells promote 
functional improvement after excitotoxic lesion of mouse striatum 
 
 
 
3.3.1. Introduction 
 Since the transplantation studies with NSCs did not result in a proper differentiation of 
the grafted cells into neurons, we decided to take advantage of the embryonic NSCs that had 
been isolated and pre-differentiated by Christian Bernreuther and Marcel Dihné in the lab of 
Melitta Schachner in Hamburg. The great interest in these cells is also well-founded because 
of the possible transfection with different target genes. Unlike the NSCs these eNSCs can 
easily be transfected and show a stable expression of transfected genes throughout the in 
vitro pre-differentiation.  
In a co-operative project, we therefore decided to transplant L1-transfected embryonic neural 
stem cells into excitotoxic lesioned animals and test their effect on functional improvement. 
Recognition molecules at the cell surface and in the extracellular matrix can favor neuronal 
survival and migration, neurite outgrowth and synapse formation not only during 
development, but also in the adult CNS after trauma. The immunoglobulin superfamily 
recognition molecule L1 (Appel et al., 1993; Kamiguchi, 2001; Lindner and Schachner, 1983; 
Moos et al., 1988; Rathjen and Schachner, 1948) supports these beneficial functions 
(Castellani et al., 2000; Chen et al., 1999; Demyanenko et al., 1999; Dong et al., 2003; 
Fransen et al., 1998b; Fransen et al., 1998a; Kleene et al., 2001; Law et al., 2003; Lemmon 
et al., 1989; Venero et al., 2004; Wolfer et al., 1998). Furthermore, L1 has been shown to 
promote functional recovery in adult rats after contusion induced spinal cord injury 
(Roonprapunt et al., 2003) and optic nerve lesion (Xu et al., 2004). Based on these findings 
Marcel Dihné and Christian Bernreuther found out that embryonic stem cells transfected to 
express L1 at the cell surface allowed for better migration and differentiation into neurons in 
the excitotoxic lesioned striatum of mice (Bernreuther et al., submitted). 
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3.3.2. Lesion size, location of the lesion and rotation behaviour 
 In order to evaluate a possible improvement of stem cell transplantation in a 
unilaterally lesioned animal, we first established the lesion parameters that lead to a 
pronounced drug-induced rotation behavior. For this purpose, we injected the QA at different 
coordinates and tested the rotation behaviour in response to amphetamine. The optimal 
correlation between the location of the lesion and a strong ipsilateral rotation after application 
of amphetamine was seen when the lesion was located in the posterio-lateral striatum. The 
coordinates used were those described in chapter 2.3.1. 
Interestingly, the lesion size did not correlate with the rotation behaviour (Fig. 3.2.1). Even in 
an animal with a very small lesion of about 30% of the striatum, the ipsilateral rotation was up 
to 90%, while a mouse with a strong lesion of almost 90% of the striatum did not show the 
ipsilateral preference in the turning behaviour. However, 8 out of 10 mice showed 
pronounced ipsilateral rotation in the behavioural test independent of the size of the striatal 
lesion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.1. Lack of correlation between lesion size and rotation 
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The mean performance in drug-induced ipsilateral rotations of each 
animal is plotted against the corresponding mean value of the lesion 
size. The lesion size was estimated as described in chapter 2.5.3 and 
drug induced rotations were measured as described in chapter 2.6.1. 
Most of the animals displayed a stable ipsilateral rotation behaviour but 
without correlation to the size of the striatal lesion. 
 
 
 
40 
3.3.3. Drug-induced rotation behaviour  
 Thirty adult C57BL/6 mice were used for the behavioural analyses. All mice received 
a unilateral striatal lesion through injection of 60nmol quinolinic acid. Mice were then 
randomly assigned to four groups, one for the transplantation of L1- ES cells (11 animals), 
one for the transplantation of L1+ ES cells (9 animals), a third group which received only a 
QA injection (QA control group) and a fourth group which received PBS instead of QA-
injections (4 animals). Drug induced rotation behaviour was tested 1, 4, 8 and 12 weeks after 
quinolinic acid/PBS lesion and cell transplantation and rotation was measured as described 
in chapter 2.6.1.  
As shown in figure 3.3.1, the rotation behaviour of the QA-lesioned animals (QA control 
group) was very stable and always clearly beyond 50%, which means that the QA-lesioned 
animals all rotated in a preferred direction. The PBS-injected animals seemed to have a 
preferred rotation in the opposite direction but with a high variance, so that it was not 
significantly different to 50% (expect 4 weeks after PBS-injection, which must be interpreted 
as a random exception). After transplantation of L1--eNSCs, the rotation behaviour did not 
differ from that of the QA-lesioned animals or was even more pronounced, assuming that the 
transplantation of the wt stem cells alone has no influence on the amphetamine-induced 
rotation behaviour. The transplantation of L1+-eNSCs on the other hand, leads to a significant 
decrease of ipsilateral rotations. This effect was already seen at 1 week after transplantation, 
where the rotation behaviour of the L1+-eNSC transplanted animals did not differ from that of 
the PBS-injected control mice – they behaved as if they had no lesion at all. The same 
observation was made 4 weeks after transplantation, but disappeared at 8 and 12 weeks 
after transplantation, where the rotation behaviour was still less pronounced as in the QA-
lesioned control animals or the L1--eNSC transplanted animals but without significance. 
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Figure 3.3.2. Drug-induced rotation behaviour after transplantation of eNSCs in 
unilaterally lesioned wt mice. 
Analysis of amphetamine-stimulated rotations in animals with unilateral quinolinic acid 
induced striatal lesion grafted either with cells differentiated to day 3 of stage 5 derived 
from L1- (n=11; grey columns) or L1+ ES cells (n=9; striped columns), and non-transplanted 
controls (n=10; black columns). Furthermore an additional group of PBS-injected animals 
was tested (n=4; white columns). Percentages of 360°-rotations ipsilateral to the lesioned 
striatum to the total number of rotations is expressed (mean ± SEM), * p < 0.05, compared 
with control group. 
 
 
3.3.4. Cylinder test 
 All animals that were tested for drug-induced rotation also performed the cylinder test 
twice a week at 1, 4, 8 and 12 weeks after transplantation of the eNSCs. The additional 
behavioural task of the cylinder test should give a more detailed impression of the natural 
behaviour and motor functions of the lesioned and transplanted animals.  
Cylinder test data were estimated and analysed as described in chapter 2.6.2. 
In contrast to the rotation behaviour-data, I could not detect a difference between any of the 
transplanted animals and the QA-lesioned control group. There is though a tendence of the 
L1+-eNSC transplanted animals towards a less pronounced imbalance in fore-limb use, but 
without significance. Only the PBS-injected animals display a normal usage of their fore-
limbs: no imbalance in the fore-limb use (Fig. 3.3.3). 
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Figure 3.3.3. Cylinder test behaviour after transplantation of eNSC  
Analysis of the fore-limb use in animals with unilateral quinolinic acid induced 
striatal lesion grafted either with cells differentiated to day 3 of stage 5 derived 
from L1- (n=11; open circles on dashed line) or L1+ ES cells (n=9; open squares 
on dashed line), and non-transplanted controls (n=10; black squares on continues 
line). Furthermore an additional group of PBS-injected animals was tested (n=4; 
black circles on continues line). Error bars show standard error of the mean 
(SEM). 
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4. Discussion 
 
 
Cell therapy in Huntington´s disease aims at restoring brain function by replacing the striatal 
projection neurons that undergo progressive degeneration in the HD patient´s brain. In 
animal models, intrastriatal grafts of fetal striatal tissue containing projection neurons re-
establish connections with the according projection areas. This level of reconstruction of 
cortico-striatopallidal circuitry is sufficient to reverse motor and cognitive deficits in rats and 
monkeys (Dunnett et al., 2000b; Kendall et al., 1998; Palfi et al., 1998). Clinical trials with 
intrastriatal transplantation of human fetal tissue support the cell replacement strategy in HD 
(Freeman et al., 2000). Although the success of fetal transplantations has so far led to 
ongoing multi-center clinical studies, there are still a number of unsolved problems. The most 
important ones are ethical concerns and the limited availability of fetal donor tissue. But also 
differences in cell survival and clinical improvement have been reported after transplantation 
of fetal striatal tissue into the brain of HD patients (Freeman et al., 2000; Hauser, 2002). 
Since stem cells are expandable and can be differentiated to GABAergic cells in vitro, they 
seem to be the perfect donor material for future transplantation studies. Several different 
types of stem cells have already been tested in vitro and in vivo in different experimental 
setups (see chapter 4.1). In the present study, the survival and differentiation potential of 
NSCs after transplantation in two different mouse models for HD were investigated. 
Furthermore, the capacity of L1 overexpressing donor eNSCs to promote functional 
improvement has also been investigated in the QA-lesioned mouse model. 
 
 
4.1. Stem cell types and stem cell preparation methods 
 During the past two decades, the knowledge and understanding of stem cells has 
increased tremendously. Their properties of self-renewal and multilineage differentiation 
make them uniquely suited as a powerful tool for the treatment of a wide spectrum of 
diseases. But using stem cells in the clinic, as a means for replacing cells that are damaged 
by disease or injury, requires the understanding of the nature and qualities of tissue-specific 
stem cells as well as the mechanisms by which such tissue-specific stem cells differentiate 
into mature, and functional units. 
As mentioned in chapter 1.4, there is a great difference between embryonic and fetal stem 
cells in regard to their differentiation potential and their capacity to undergo self-renewal 
while maintain their developmental potential. In the present studies, NSCs from the fetal 
striatum were used because of their inherent potential to give rise to specific striatal cells. 
44 
After isolation of the mouse fetal tissue, the NSC were grown in vitro to expand their number 
through several passages prior to transplantation into the HD mouse models. 
The experiments of this thesis with NSC transplants into QA-lesioned mice demonstrate that 
the method of graft preparation as well as the timing of the transplantation procedure strongly 
affect the survival of NSCs. Compared their transplantation as a single cell suspension, NSC 
demonstrated much better survival when transplanted as intact spheres (Fig. 3.1.2 and 3.1.3). 
In vitro, neural stem cells grow spontaneously as neurospheres, which are known to be 
heterogeneous, containing both multipotent cells with stem cell-like characteristics as well as 
more restricted progenitor cell populations at different stages of differentiation (Reynolds and 
Weiss, 1996; Suslov et al., 2002). Caldwell and colleagues reported that neurospheres from 
human neural stem cells were able to survive and differentiate much better than single cells 
when plated onto poly-L-lysine/laminin-coated culture flasks (Caldwell et al., 2001). When 
plating the mouse NSCs onto poly-L-lysine coated substrate, I observed the same effect. The 
transplantation of intact spheres avoids the mechanical trauma associated with dissociation 
and may be responsible for the improved survival of the donor neurospheres. It may also be 
important that the cells inside the spheres maintain communication with neighboring cells 
and benefit from either soluble factors or cell-cell contact itself. 
Neurospheres that were transplanted 2 days after QA-lesion displayed a graft volume that 
was much larger than in all other experimental approaches. When multiplied by the 
measured cell density, the estimated total cell number of these grafts was about 20,000 two 
weeks after implantation, which corresponds to the amount of cells that were initially 
transplanted. Therefore one possible interpretation is that almost all donor cells survived 
when they were transplanted as a neurosphere suspension 2 days after inducing the lesion. 
When these neurosphere grafts were examined after 3 months survival time, the graft 
volume was dramatically reduced, which leads to the assumption that either the donor cells 
had died in the meantime or that EGFP-expression had become down-regulated, to the 
extent that some donor cells were no longer detectable. Such down-regulation of EGFP has 
also been described elsewhere and needs to be further investigated (Akerud et al., 2001; 
Bosch et al., 2004; Eriksson et al., 2003; Martinez-Serrano and Bjorklund, 1997). 
Three months after transplantation the majority of the grafted neurospheres had down-
regulated nestin expression but also failed to express any of the neuronal or oligodendroglial 
markers. As already described by others most of the donor cells expressed the astroglial 
marker GFAP (Lundberg et al., 1997; Rubio et al., 2000). Although the inefficient 
differentiation of NSCs is a common observation in stem cell transplant experiments 
performed in adult injured CNS, the reason for this behaviour is still unclear but seems to 
depend on the host tissue (Boockvar et al., 2005; Cao et al., 2002; Lundberg et al., 1997). 
However, when NSC are transplanted directly after isolation from the embryonic lateral 
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ganglionic eminence tissue, the cells are capable of differentiating in a site-specific manner 
and can integrate into the host tissue (Eriksson et al., 2003). Similar to fetal striatal 
transplants, these graft suspensions are able to differentiate into specific populations of 
neurons (Brasted et al., 1999; Clarke et al., 1988; Dunnett et al., 1988; Sirinathsinghji et al., 
1988). Recent observations have reported that the differentiation potential of NSCs depends 
on the donor age: NSCs isolated from embryonic tissue at E12 and E13 displayed better 
neuronal differentiation than those isolated from E14 animals (O' Keeffe and Sullivan, 2005). 
Furthermore, it has also been demonstrated that the differentiation potential of murine and 
human NSCs is reduced with each passage in vitro (Jain et al., 2003). This may be due to 
the passage-induced dilution or replacement of soluble molecules, such as growth factors. 
Other groups have already shown that the cellular composition and growth properties of 
expanding NSCs depend on the growth factors used in vitro (Caldwell et al., 2001; Svendsen 
and Caldwell, 2000). For future experiments, it is therefore indispensable to identify the 
appropriate factors that can maintain the differentiation potential of NSCs in vitro. An 
alternative strategy, which has already been studied by several groups (Bosch et al., 2004; 
McBride et al., 2004; Vescovi and Snyder, 1999) is the predifferentiation of the donor cells 
before grafting. 
 
Unlike NSCs, ES cells are not restricted in their developmental potential. The neural 
differentiation of pluripotent cell lines has the advantage of extending the range of different 
cell types that can be studied in cell culture. Murine ES cell lines have been used effectively 
to generate neurons and glia in vitro and differentiation protocols have been developed to 
obtain neural progenitor cells (Brustle et al., 1997; Fraichard and Chassande, 1995; Li et al., 
1998; Okabe et al., 1996; Strubing et al., 1995). Furthermore, specific subpopulations of 
neurons derived from ES cells express markers characteristic for motor neurons and 
interneurons, suggesting high levels of differentiation along specific neuronal pathways 
(Renoncourt et al., 1998). The success with which ES cells can be differentiated into mature 
neurons contrasts with that of differentiated neural stem cells which displayed 
electrophysiological characteristics of only immature neurons only (Balasubramaniyan et al., 
2004; Whittemore et al., 1999). 
Another advantage of ESCs is the possibility of genetic manipulation. Unlike neural stem 
cells, which can only be transformed using viral approaches, ES cells are easily transformed 
in the early stages after isolation from the blastocyst and offer many advantages for potential 
cell and gene therapies. The experimental approaches of Dihné and Bernreuther, using L1-
expressing neural progenitor cells derived from embryonic stem cells, showed in vitro that L1 
expression by these eNSCs increases neuronal differentiation without changing the 
transmitter-specific phenotype. eNSCs differentiated three days in vitro and injected into the 
46 
centre of the lesion two days after injection of quinolinic acid were identified by EGFP 
expression two months later. L1+ grafts showed a 2-fold increase in neurons versus L1- grafts. 
Correspondingly, differentiation into GFAP+ astrocytes decreased. Myelin basic protein+ 
oligodendrocytes were hardly detectable in both groups. L1+ grafted cells were also 
increased in neuronal and decreased in astrocytic differentiation in vivo in the quinolinic acid 
lesioned mouse striatum (Bernreuther et al., 2005, submitted). The results of the present 
experiments, in which possible functional improvement following grafting of L1+ and L1- cells 
was tested, revealed that the L1+ cells could improve the drug-induced rotation behaviour, 
suggesting that they have a positive influence on striatal physiology after QA-lesion. Since 
that effect was not confirmed by the cylinder test and almost completely lost after a graft-
survival time of 8 weeks, it is questionable, whether the improvement can be due to 
differentiated donor neurons that connect to the host cells. It is likely that the improvement 
might be due to the L1-expression of the transplanted cells, since there is no beneficial effect 
on the rotation behaviour after transplantation of L1- cells. This suggestion is strengthened by 
the fact that the eNSC graft seems to shrink over time, (Bernreuther et al., 2005, submitted). 
However, a great problem in ES cell transplantations is the possibility of tumor formation. 
Transplantation of undifferentiated ES cells into animals results in the formation of 
teratocarcinomas, which are tumors bearing a variety of tissue morphologies characteristic of 
uncontrolled differentiation (Robertson, 1987). While ES cell neural transplantation 
experiments have indicated that tumors do not form after neural differentiation (Brustle et al., 
1997; Dinsmore et al., 1996), there is still considerable concern about this possibility. In the 
experiments with eNSC transplantations in QA-lesioned animals, the ES cells were not only 
predifferentiated to neural precursor cells expressing nestin, but also pretreated by removal 
of the growth factors EGF and bFGF for three days in vitro to induce further predifferentiation. 
Even under these stringent condition, about 17% of the transplanted animals developed 
tumors at the transplantation site (personal communication with Bernreuther and Dihné). 
These observations demonstrate that even singular undifferentiated cells within the graft may 
have the potential to induce tumor growth. More needs to be understood regarding the 
control of differentiation before effective and safe therapies can be developed with ES cells. 
 
 
4.2. Animal models for HD in comparison to the human disease 
Despite the intrinsic factors of the stem cells that play a role in survival and 
differentiation in vitro and after transplantation, they also react to environmental properties 
and are strongly influenced by the surrounding host tissue in vivo. To follow the aim of stem 
cell transplantations in HD patients, it is therefore indispensable to investigate the graft-host 
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interactions and make sure that animal models reproduce, as close as possible, the main 
pathological features of the human disease. 
The striatal QA-lesion is such a well established model for Huntington´s disease in rodents, 
since it reproduces several key neuropathological features, including death of medium-sized 
spiny neurons and sparing of interneurons (Beal et al., 1986; Beal et al., 1989). The acute 
astroglial response has been reported to take place within the first 7 days after excitotoxic 
lesion (Dusart et al., 1991; Isacson et al., 1987), while the microglial reaction was already 
evident one day post lesion (Marty et al., 1991; Topper et al., 1993). When NSCs were 
grafted at different time intervals after QA-lesion, donor cell survival was much better when 
the transplantation took place early after the lesion. The reason for the poorer survival of 
donor cells grafted at 7 or 14 days post QA lesion might be related to the glial reaction of 
both astrocytes and microglia. This lead to the investigation of the acute glial reaction in the 
mouse striatum after excitotoxic lesion. It could be observed that the early glial reaction in the 
mouse striatum 2 days after the injection of QA was still moderate. Even the microglial 
activation was not very pronounced at 2 dpo, but increased dramatically during the first week 
after the lesion (Fig. 3). In addition, the morphology of the cells was different at 2 dpo in 
comparison with their appearance one or two weeks later. At 2 dpo, microglia might have 
been in a different physiological condition compared to 7-14 dpo, producing correspondingly 
different effects on the grafted cells. It has been demonstrated that tissue cultured microglia 
release molecules that are able to rescue neurons from apoptotic death and that, as yet 
unidentified diffusible signals from apoptotic neurons enhance microglial neuroprotective 
properties, while this effect is abolished or even inverted without the contact of apoptotic 
neurons (Polazzi et al., 2001; Zietlow et al., 1999). In the early phase after QA injection, it is 
possible that microglia might have had neuroprotective properties whereas later, they may 
have changed their function and become neurotoxic. This could be one of the reasons for the 
decreased graft survival in our experiments. 
Similar to the microglial reaction, the astrogliosis was moderate at 2 dpo (Fig. 3.4). Again, a 
positive influence on the degenerating tissue is possible in the early phase following brain 
injury, where astrocytes can rescue damaged neurons (Chen and Swanson, 2003; Yoshida 
and Toya, 1997). Several phases of astroglial changes after excitotoxic lesion have been 
reported (Dusart et al., 1991), and Liberto and colleagues (2004) recently reviewed two 
different forms of astrogliosis after brain insult which closely relate the present data: 
isomorphic and unisomorphic gliotic changes with opposing effects on the degenerating 
tissue. The isomorphic astrocytic reaction is described as less dramatic where astrocytes 
remain stellar shaped (astrocyte activation). This moderate form of astrocgliosis is 
considered as adaptive and beneficial to restoring homeostasis. In contrast, the 
unisomorphic gliotic reaction, which is described in the subsequent phase of scar formation, 
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exacerbates tissue damage (Liberto et al., 2004). Activated astrocytes secrete growth factors 
such as glial derived neurotrophic factor (GDNF; Marco et al., 2002) and nerve growth factor 
(NGF; Strauss et al., 1994) while scar-forming astrocytes release pro-inflammatory cytokines 
such as tumor necrosis factor alpha (TNF-α; Acarin et al., 2000). Since in our transplantation 
experiments there was no need for immunsuppression and no additional glial change due to 
the transplantation could be detected, our studies of the astro- and microglia reaction are in 
accordance with the steps described by Liberto and colleagues. Thus in the present 
experiments the host tissue might have presented a more beneficial environment for the 
transplants early after the QA lesion because of a possible cytoprotective function of 
microglia and the isomorphic astrogliosis. The environmental influence on the grafted cells 
may have changed at 7 and 14 dpo because microglia might have become cytotoxic and 
astrocytes started to form a scar. This hypothesis is corroborated by the fact that donor cells 
showed better survival in the lesioned striatum 2 dpo than in the unlesioned control. 
Since a great influence of the timing of transplantation on survival of the grafted cells was 
detected, this effect could be due to changing BDNF-levels in the striatum after QA-injection. 
It has been shown that NSCs express the BDNF-receptor TrkB (Benoit et al., 2001) and are 
responsive to BDNF in vitro (Ciccolini and Svendsen, 2001). BDNF, derived from cortical 
afferents, constitutes the most important survival factor for striatal projection neurons (Perez-
Navarro et al., 2000) and plays a role in the differentiation of these cells (Mizuno et al., 1994; 
Nakao et al., 1995; Ventimiglia et al., 1995). In the cortical neurons projecting to the striatum, 
mRNA-expression of BNDF is increased 4-6 h after QA lesion of the striatum and returnes to 
control levels after another 20 h (Baquet et al., 2004; Canals et al., 2001). Although Canals 
and colleagues also showed that mRNA expression of BDNF in the striatum remained 
constant after QA injection, it is likely that an increase of the BDNF protein-level would take 
place shortly after excitotoxic lesion, possibly evoked by an increase of BDNF-transport from 
the cortical projection neurons. Unexpectedly, the protein concentration, measured by 
relative immunoactivity, did not change up to 14 dpo, at which time a slight decrease (to 
90%) from control levels was observed. Thus BDNF seems not to be the crucial factor that 
influences graft survival. 
If one draws an analogy between the striatal tissue at 2 days after the QA-lesion with that of 
patients during the early earlier stages of Huntington´s disease, and the 7 day lesion with 
that of the later stages of the disease, the present data would suggest that transplantation of 
stem cells should be performed when the gliosis is still in a moderate phase and glial cells 
can be beneficial, rather than detrimental, to cell survival. It should be noted that several 
transplantation studies performed with animals are timed early after QA-lesion (Armstrong et 
al., 2000; Hurelbrink et al., 2002). This however does not provide a good model for the 
symptomatic HD patients, in whom transplantation studies are currently being performed 
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(Bachoud-Levi et al., 2000; Peschanski et al., 2004). Taking into account all due caveats, the 
present data suggests that cell transplantation in HD patients should be considered in early 
stages of the disease rather than the later phases, by which time the glial scar may have 
already developed and is likely to be detrimental for graft survival. 
Although the QA-lesion model mimics many of the neuropathological features of HD, it does 
not reproduce the pathogenetic process of the human condition. The lesion model can be 
regarded as a static model, where a strong degenerative process takes place after the 
injection of the cytotoxin and results in the loss of GABAergic neurons. In contrast to this 
model, the transgenic mice carrying the human exon 1 with a greatly expanded (115-150) 
CAG repeat lengths, develop a progressive pathophysiological phenotype (Mangiarini et al., 
1996). The R6/2 line, which was also used in the present experiments, exhibits the 
development of behavioural phenotype involving ataxia, tremor, and a epileptic tendency 
from 8 weeks of age (Mangiarini et al., 1996). Since these mice show rather little overt cell 
death, at least until the very latest stage of the disease, but a shrinkage and dysfunction of 
the projection neurons, they represent the neuropathology of the earlier stage of HD. At this 
stage, neuronal intranuclear inclusions have developed but the striatal projection neurons 
have not yet died. When NSCs were transplanted into the striatum of R6/2 mice, the grafted 
cells were more widely distributed throughout the host tissue and formed more processes 
than after transplantation into the QA-lesioned striatum. Their differentiation in vivo was 
similar to that of the NSC grafts in the QA-lesioned striatum: most of the cells expressed the 
astroglial marker GFAP (Fig. 3.1.8). However, they also displayed the expression of the glial 
progenitor marker NG2, suggesting that the cells are not yet fully differentiated and are still 
able to form either oligodendrocytes or astrocytes. This also demonstrates that the same 
cells can develop different features when transplanted into different tissues. Because of the 
lack of neuronal degeneration and the early death of R6/2 mice, it is difficult to study cell 
replacement strategies in this mouse model. Though the donor cells seemed to survive just 
as well as in the QA-lesion model, long-term survival could not be investigated over a period 
of more than 4 weeks, which cannot be enough to estimate long-term functional aspects of 
the grafted cells. A lack of functional improvement after transplantation of fetal striatal tissue 
into the R6/2 mice has been reported by Steve Dunnett and colleagues. Although the internal 
organisation of the grafted fetal tissue was similar to that of the grafts in the excitotoxic 
lesioned striatum, they did not seem to have any physiological influence on the host circuits 
(Dunnett et al., 1998). Since neuronal degeneration in the HD patients takes place not only in 
the striatum but also in the cortex and other basal ganglia nuclei, it is not known whether 
these areas may contribute to many of the symptoms of the disease that would not be 
amenable by explicit striatal repair by cell transplantation. R6/2 mice show neuropathological 
features like neuronal intranuclear inclusions also in other regions of the brain, what might be 
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another reason for the lack of functional improvements after striatal transplantation of the 
fetal tissue. Van Dellen and colleagues strengthened this idea when they showed that the 
anterior cingulated cortex is an important area of pathology in the HD transgenic mice, and 
that transplantation of wild-type donor cortex into the anterior cingulated cortex of these mice 
was found to delay the onset of a specific motor deficit, i.e. rear-paw clasping (van Dellen et 
al., 2001). 
Obviously, there is the need for improved animal models that might offer at least initial clues 
to the potential viability of present and pending clinical trials. 
 
 
4.3. Neural stem cell transplantations as a therapeutic approach for HD: hopes and 
fears 
 Huntington´s disease is a severe neurodegenerative disorder that leads to death 
within approximately 15-20 years. So far, there is no curative therapy available, and although 
disturbances of mood and hyperactivity can be somewhat treated, the cognitive symptoms 
and the progression of the disease remain unaffected. The contemporary search for 
therapies at the cellular level to protect or slow cell death and to replace lost cells by 
transplantation has provided many hopes of HD patients and their families. 
Because of the remarkable capacity of fetal striatal grafts to reconstruct neural circuitry with 
the recovery of motor and cognitive deficits in the animal model of HD, the transplantation of 
fetal tissue has already been carried out in a number of HD patients. The early studies from 
Cuba, Czechoslovakia, and Mexico City, were performed in 1990, each provided brief clinical 
accounts of implantation protocols and reported that the procedures were achieved without 
major complications or side effects. Each of these studies involved tissue implantation within 
1-2h of spontaneous abortion of the donated human fetal tissue, whereas most subsequent 
studies have been based on tissue donation from elective abortion. In either case, there are 
sensitive ethical and social issues associated with using human fetal tissue for 
transplantation. This makes it imperative that such studies be undertaken only within a 
framework of strict ethical appraisal and informed consent (Boer, 1994). Many clinical trials 
have been performed so far, transplanting human fetal tissue into the brains of HD patients 
leading to ongoing multi-center trials (including six centers of the United Kingdom arm of the 
European network for striatal transplantation ( “NEST-UK”, for review also see Dunnett and 
Rosser, 2004). One great problem of tissue transplantations is the compatibility of donor 
tissue to the host. Patients who had received fetal transplants must be treated with 
immunosuppressive medications to avoid severe rejection of the graft. This means an 
additional stress for the patient, because immunosuppressive medication is necessary before 
and after the severe and complicated surgery but still a loss of the grafted tissue due to a 
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severe graft-versus-reactionhost does occasionally occur. However, the major problem in 
developing a tissue-based therapeutic approach is the very limited availability of suitable 
donor tissues. There might be advances in adaption of the collection methods (Freeman et 
al., 2000) and better storage and hibernation protocols (Hurelbrink et al., 2003), but donor 
tissue based on the use of fresh primary fetal tissues, whether from elective or spontaneous 
abortion, can never achieve the levels of standardization and quality control required for a 
practical experimental medicine. Therefore, the existing trials must be considered “proof of 
principle” until a more reliable, standardized source of tissue can be found. 
The alternative sources of donor material for a therapeutic approach of cell replacement in 
HD are stem cells, especially NSCs from the primordial of the striatum, the ganglionic 
eminence. Although the ethical problem of gaining such cells through isolation from the 
human fetal tissue sill remains, it is not as severe since NSCs, once isolated from the tissue, 
can self-renew in vitro and therefore are expandable to great numbers. 
Despite the advantage of better availability, stem cells, as a source for cell replacement 
therapies remain an area of controversy and heated debate. Although NSCs do exhibit 
remarkable degrees of plasticity with regard to lineage potential, this endogenous potential is 
not sufficient to overcome the necessity of instructive signals coming from the local 
environment. The type and physiology of the host tissue influences the differentiation and 
migration of the transplanted donor cells. This has been described by many groups (Cao et 
al., 2001; Chow et al., 2000; Fricker et al., 1999; Gage, 2000; Lundberg et al., 1996; 
Lundberg et al., 1997) and could be confirmed in our experiments, where NSC graft survival 
and differentiation depended on the host tissue environment. The differentiation of NSCs into 
GABAergic neurons after intrastriatal transplantation in a HD mouse model has, so far, only 
been described by Bosch and colleagues (Bosch et al., 2004). However, since they used an 
immortalized cell linage of NSCs, their protocol cannot be directly applied to primary NSCs. 
Therefore, further basic research is necessary to explore, how to generate and select striatal 
projection neurons from stem cells. Subsequent studies should be able to show that these 
neurons survive transplantation, become anatomically and functionally integrated, and 
improve motor and cognitive function in Huntington´s models. 
ES cells might be such an alternative. As mentioned before, they can be genetically modified 
to over-express i.e. growth factors or adhesion molecules to improve their integrity and 
differentiation potential. In this thesis the example of eNSCs transfected with L1 showed that 
there is an improvement even in the behaviour of the animals transplanted with these cells. 
However, the great risk in transplanting ES cells is the tumor formation in vivo. Before we 
might start considering ESC transplantations as a therapeutical approach, this problem 
needs to be solved. 
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Taken together, the development of stem cell-based therapies for neurodegenerative 
disorders like Huntington´s disease is still in an early stage. First of all, important ethical and 
social constraints that relate to the sources of human stem cells to be used for research or 
clinical applications have to be overcome (McLaren, 2001). And because many patients 
focus on the new cellular therapy as a last hope for an improvement of their daily life, 
information about the achievements need to be communicated to the public promptly, but in 
a rigorous and cautious manner. 
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5. Summary 
Cell replacement therapies for neurodegenerative diseases using stem cells require above 
all a good survival of the graft and therefore an understanding of the possible influence of the 
surrounding degenerating tissue on the grafted cells. In this thesis, I report on the 
experiments of stem cell transplantation in mouse models for Huntington´s disease. The 
most common rodent model for HD is the QA-lesion model, where quinolinic acid is injected 
unilaterally into the striatum of adult rats. We adapted this method for use in mice and 
transplanted syngeneic embryonic and fetal neural stem cells of enhanced green fluorescent 
protein (EGFP)-transgenic mice into the QA-lesioned striatum. Since the glial cells react very 
strongly to the excitotoxic lesion, we examined both, astrocyte and microglia activation, at the 
site of transplantation, assuming an influence of activated glia on graft survival. In order to 
investigate the best timing of transplantation for the survival of donor cells, we transplanted 
fetal NSCs at 2, 7 and 14 days after injury. In addition, the influence of graft preparation prior 
to transplantation (i.e. intact neurospheres vs. dissociated cell suspension) on graft survival 
was investigated. At all transplantation dates we found that grafted neurospheres 
demonstrated better survival than single cell suspensions. By far the best survival was found 
when transplantation was performed early (2 days) after QA-lesion. At later transplantation 
dates, a decrease in graft survival was accompanied by an increasing astrocyte and 
microglia activation. We also investigated brain derived neurotrophic factor (BDNF)-
expression in the striatum after QA-lesion, but there was no significant change in BDNF 
protein-level. Long term survival of NSCs transplanted 2 dpo showed that most of the cells 
expressed GFAP, suggesting astrocytic differentiation. Another mouse model for HD is the 
R6/2 mouse which carries the human exon 1 of the huntingtin gene, including the causative 
CAG repeats. These animals display a different neuropathology and therefore might be seen 
as a model for the early stage of HD. When we transplanted NSCs into the striatum of these 
mice, we found that graft morphology was somewhat different to that in the QA-lesioned 
striatum and transplanted cells expressed not only GFAP, but also the oligodendroglial 
precursor marker NG2. This also points to the influence of the host tissue environment on 
graft physiology. As a cooperation project with the research group of Prof. Melitta Schachner, 
we also investigated genetically manipulated embryonic NSCs after transplantation into the 
QA-model. Professor Schachners group transfected ES cells with the cell adhesion molecule 
L1 and already found an improved in vivo differentiation potential. In follow up experiments, 
we have investigated the possible functional outcome of such transplantations with the help 
of two different behavioural tests. Since a functional improvement could only be seen in one 
of the tests which subsequently diminished at 8 weeks after transplantation, it is not clear, 
whether these cells have the capacity to integrate into the tissue properly. Thus, despite the 
enhanced differential potential of the eNSCs, they fail to adopt the function of the missing 
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striatal neurons. Furthermore, a number of the L1 expressing grafts went on to form tumours, 
highlighting the continued need for extreme vigilance when exploring the therapeutic 
potential of such cells. 
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7. Abbreviations 
 
ANOVA – Analysis of Variance 
bFGF – Basic fibroblast growth factor 
BDNF – Brain derived neurotrophic factor 
BSA – Bovine serum albumine 
CAG – Cytosin-Adenin-Guanin 
CD11b – Cluster of differentiation 11b 
CNPase - Cyclic nucleotide 3´-phosphodiesterase 
CNS – Central nervous system 
CNTF – Ciliary neurotrophic factor 
DAB – Diamino-benzidine 
DAPI – 4´, 6-Diamidino-2-phenylindole 
DARPP-32 – Dopamine and camp regulated posphoprotein 32 kDa 
DMSO – Dimethyl sulfoxide 
DNA – Desoxyribonucleic acid 
dpo – days post operation 
DPX – 3-cyclohexyl-6-dimethylamino-1-methyl-1H-1, 3, 5,-triazine-2, 4-dione 
EGF – Epidermal growth factor 
eNSC – embryonic neural stem cell 
ESC – embryonic stem cell 
GABA – Gamma-aminobutyric acid 
GDNF – Glial derived nerve growth factor 
GFAP – Glial fibrillic acid protein 
EGFP – Enhanced green fluorescent protein 
HEPES – N-2-Hydroxyethylpiperazine-N´-2-ethanesulfonic acid 
HD – Huntington´s disease 
HRP – Horseradish peroxidase 
IC – Immuncytochemistry 
IgG – Immunglobulin G 
IHC – Immunhistochemistry 
IR – Immunreactivity 
LGP – Lateral globus pallidus 
MAP-2 – Microtubulin associated protein-2 
MGP – Medial globus pallidus 
NGF – Nerve growth factor 
NeuN – Neuronal nuclei 
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NIH – National Institute of Health 
NSC – Neural stem cell 
PBS – Phosphate buffered saline 
PCR – Polymerase chain reaction 
PGK – 3-phoshoglycerokinase 
PFA – Paraformaldehyde 
PLL – Poly-L-Lysine 
PLO – Poly-L-Ornithin 
QA – Quinolinic acid 
RA – Retinoic acid 
RT – Room temperature 
SDS-PAGE – Sodium-dodecylsulfate-polyacrylamide gel electrophoresis 
SEM – Standard error of the mean 
SNr – Substantia nigra pars reticulata 
STN – Nucleus subthalamicus 
TBST – Tris buffered saline with Tween 20 
tg – Transgenic 
TNF-α – tumor necrosis factor alpha 
TrkB – Tyrosin kinase B 
wt – wild type 
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Zusammenfassung 
 
Die Vorstellung einer Zellersatztherapie mit Hilfe von Stammzellen ist mit vielen Hoffnungen 
für die Heilung verschiedenster Krankheiten verbunden. Stammzellen besitzen die 
einzigartige Fähigkeit, sich zu allen Arten von Körperzellen zu differenzieren und es ist eine 
große Herausforderung für die Wissenschaft, diese Zellen zu studieren. Endlich scheint es 
möglich zu werden, die Entwicklung eines jeden Zelltyps zu entschlüsseln und gezielt 
nachzuahmen. Dieser Gedanke führt zu der wunderbaren Idee, jedes kranke Organ im 
Körper durch eine Transplantation von funktionsfähigen, neuen Zellen zu heilen. 
Eine solche Regeneration findet an vielen Orten im Körper ganz natürlich satt. Alte Zellen 
werden durch neu gebildete, funktionsfähige Zellen ersetzt. Die dazu nötigen komplizierten 
inter- und intrazellulären Prozesse laufen jedoch nicht bei allen Körperzellen so reibungslos 
ab. Sie werden durch äußere oder genetische Faktoren verhindert oder nach einer 
bestimmten Lebenszeit schlicht abgeschaltet. Obwohl Nervenzellen und ihre Verknüpfungen 
während und kurz nach der Embryonalentwicklung noch dynamisch und regenerationsfähig 
waren, gehen ihnen diese Fähigkeiten mit zunehmendem Lebensalter gänzlich verloren. 
Wenige, vereinzelte Regionen im Gehirn haben auch im adulten Organismus noch die 
Fähigkeit, neugeborene Nervenzellen zu bilden. Fasziniert versucht man auch diese so 
genannten adulten Stammzellen zu begreifen mit der Vision, die Bildung dieser Zellen 
verstärken zu können.  
Die Schüsselfragen bei der Entwicklung von erfolgreichen Zellersatztherapien, sind jedoch 
nur schwer zu beantworten: 
Können die neuen (möglicherweise transplantierten) Zellen im Gewebe überleben? Und 
welchen Einfluss hat das umliegende, kranke Gewebe auf das Überleben und Verhalten 
dieser Zellen? 
 
In der hier vorliegenden Arbeit habe ich auf Grundlage eines Tierexperimentellen Modells für 
die Huntingtonsche Krankheit Überleben und Entwicklung Neuronaler Stammzellen nach 
Transplantation in das Striatum von Mäusen untersucht. 
Das bekannteste Tiermodell für diese neurodegenerative Erkrankung ist das Quinolinsäure 
(QA)- Modell. Dabei wird die neurotoxische Quinolinsäure in eine Gehirnhälfte von Ratten 
injiziert. Hierdurch kommt es zu einer definierten Läsion desjenigen Gehirnteils, der auch bei 
der Huntingtonschen Krankheit am meisten betroffen ist (das Striatum). Ein bestimmter 
Zelltyp im Striatum stirbt ab und die umliegenden Zellen reagieren darauf mit 
Entzündungsreaktion und Narbenbildung. In meinen Experimenten habe ich fetale Maus-
Stammzellen in die Gehirne von Mäusen nach einer solchen QA-Läsion transplantiert und 
das Überleben sowie den Einfluss der degenerativen Prozesse des umliegenden Gewebes 
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untersucht. Dabei wurden Stammzellen aus EGFP-exprimierenden Mäusen des gleichen 
genetischen Hintergrunds eingsetzt. Dieses EGFP ist ein grün fluoreszierendes Protein, das 
in jeder Körperzelle dieser Mäuse exprimiert wird. Das heisst, alle Zellen dieser Maus 
leuchten nach entsprechender Anregung mit Licht einer bestimmten Wellenlänge grün – die 
ganze Maus leuchtet. So auch die Stammzellen, die man dadurch nach der Tranplantation 
problemlos unter einem Fluoreszenz-Mikroskop lokalisieren kann.   
Um den besten Zeitpunkt für die Transplantation nach der Läsion zu finden, haben wir die 
Neuralen Stammzellen 2, 7 und 14 Tage nach der QA-Läsion in das lädierte Striatum injiziert. 
Zusätzlich haben wir zwei verschiedene Präparationen von Stammzellen verglichen. Da 
Neurale Stammzellen im Reagenzglas (in vitro) als Sphäroide wachsen - freischwimmende, 
sich zentrisch vergrößernde Kugeln aus Zellen, kann man sie als solche transplantieren oder 
vorher vereinzeln und eine Suspension aus Einzelzellen injizieren. 
Ich habe mit Hilfe vieler Transplantationsexperimente herausgefunden, dass die 
Stammzellen, als Sphäroide transplantiert, besser überleben, als die zuvor vereinzelten 
Zellen. Das Überleben der Zellen wurde immer zwei Wochen nach der Transplantation 
gemessen. In vielen Gehirnschnitten im Bereich der Transplantation wurde hierzu die Größe 
und Dichte des Transplantats bestimmt. Bei vergleichbarer Dichte variierte die Größe des 
Transplantats mit dem Zeitpunkt der Transplantation nach Läsion. So konnten die größten 
Zell-Transplantate nach Transplantationen, die nur 2 Tage nach der Läsion erfolgt waren, 
gefunden werden. Zu späteren Zeitpunkten nach der Läsion (7 und 14 Tage) verschlechterte 
sich das Überleben der Zellen, die Größe der Transplantate nahm drastisch ab. 
Bekanntermaßen nimmt die Entzündungsreaktion und Narbenbildung des lädierten Gewebes 
genau in dieser Zeit stark zu. Ich habe diese Reaktionen der Astrocyten und Microglia durch 
Gewebefärbungen in Gehirnschnitten dokumentiert und ausgewertet und fand einen großen 
Unterschied in Konzentration und Morphologie dieser beider Zelltypen 7 und 14 Tage nach 
der Läsion. Dieser zellulären Veränderung des Gewebes muss eine entsprechende 
Veränderung auf Molekül-Ebene vorausgehen. Eine meiner Vermutungen war, dass die 
Konzentration des Wachstumsfaktors BDNF, der besonders für das Überleben der striatalen 
Nervenzellen von großer Bedeutung ist, nach einer QA-Läsion abnimmt. Zum einen, weil die 
entsprechenden Empfängerzellen absterben und die umliegenden Zellen keinen Grund mehr 
haben, BDNF auszuschütten und zum anderen, weil das Gewebe nun umschaltet von einer 
erhaltenden Funktion zu einer Aufräum-Funktion, im Zuge derer sich das gesamte Gewebe 
physiologisch wie morphologisch verändert. Eine Änderung der BDNF-Konzentration konnte 
durch meine Experimente allerdings nicht nachgewiesen werden.  
Weiterhin habe ich die Diffrenzierung der transplantierten Zellen untersucht. Mit Hilfe 
verschiedener Zellmarker, die spezifisch einzelne Zelltypen markieren, habe ich versucht, die 
weitere Entwicklung der transplantierten Zellen sichtbar zu machen. Alle Zellen wurden 3 
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Monate nach Transplantation mit Zellmarkern für Nerven- und Gliazellen angefärbt. An hand 
der Co-Lokalisierung mit EGFP konnte versichert werden, dass es sich bei der gefärbten 
Zelle nicht um eine Zelle des umliegenden Gewebes handelte. 
Die meisten Zellen konnten mit einem Marker gegen GFAP angefärbt werden. GFAP ist ein 
Protein, das in Astrocyten gebildet wird. Die meisten transplantierten Zellen scheinen sich 
also im verletzten Gewebe fast ausschließlich zu diesem schon in Vielzahl vorhandenen 
Gliatyp zu entwickelt, der vor allem an der Narbenbildung des Gewebes beteiligt ist. Ich 
konnte keine einzige Zelle innerhalb aller Transplantate finden, die einen Nervenzell-Marker 
exprimierte – das heißt, es gab in meinen Experimenten keinen Hinweis darauf, dass die 
transplantierten Zellen sich im kranken Gewebe zu dem Zelltyp entwickeln, der zuvor durch 
die Läsion abgestorben war. 
 In Experimenten mit einem weiteren Tiermodell für die Huntingtonsche Krankheit 
habe ich daraufhin erneut Neurale Stammzellen transplantiert und die Entwicklung der Zellen 
untersucht. Bei diesem Modell handelte es sich um transgene Mäuse, denen ein humanes 
Huntington-Gen eingefügt wurde und die in kurzer Zeit ähnliche, klinische Symptome 
aufweisen, wie die Menschen, die an der Huntingtonschen Krankheit leiden. Außerdem ist in 
diesem Tiermodell die Reaktion des umliegenden Gewebes (vornehmlich der Gliazellen) auf 
die progressive physiologische Veränderung durch die Krankheit im Vergleich zu der 
plötzlichen Läsion im zuvor genannten Modell sehr viel schwächer bzw. fast nicht vorhanden. 
In meinen Experimenten fand ich heraus, dass die transplantierten Zellen sich besser 
innerhalb des sie umgebenden Gewebes verteilten und eine stärker definierte Morphologie 
aufwiesen. Doch auch diese Zellen entwickelten sich ausschließlich zu Gliazellen und nicht 
zu den durch die Krankheit verminderten Nervenzellen. 
 In einem Kooperations-Projekt zusammen mit der Arbeitsgruppe um Prof. Melitta 
Schachner aus Hamburg haben wir zusätzlich Experimente mit embryonalen Stammzellen 
durchgeführt. Dabei habe ich das Verhalten der transplantierten Tiere mit Hilfe spezifischer 
Tests untersucht. Die transplantierten Zellen wurden von unseren Kooperationspartnern 
genetisch verändert. In Vorversuchen konnte eine verbesserte Differenzierung nach 
Transplantion in das QA-Modell nachgewiesen werden. Zum ersten Mal schien es, als 
entwickelten sich Stammzellen tatsächlich zu den Nervenzellen, die im Gewebe gebraucht 
wurden. In vielen Verhaltenstests mit transplantierten und Kontroll-Tieren konnten wir zeigen, 
dass das Verhaltens-Defizit, das sich üblicherweise nach einer QA-Läsion zeigt durch die 
Transplantation der genetisch veränderten embryonalen Stammzellen vorübergehend 
verbesserte. Da dieser Effekt in nur einem von zwei Tests nachgewiesen werden konnte und 
nur für kurze Zeit nach der Transplantation anhielt (zwischen 4 und 8 Wochen), scheint auch 
den hier verwendeten Zellen die Fähigkeit zu fehlen, sich dauerhaft funktional in das kranke 
Gewebe zu integrieren und die durch die Läsion verursachten Symptome zu verbessern. 
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Zudem kam es in etwa 17% der Tiere zur Tumorbildung nach Transplantation, da die 
embryonalen Stammzellen noch immer in der Lage waren sich unkontrolliert zu teilen. 
 
Als Fazit dieser Dissertation kann man die Schwierigkeit der Umsetzung einer simplen Idee 
im Falle der Stammzell-Ersatztherapie zur Heilung von neurodegenerativen Erkrankungen 
bereits im Tiermodell erkennen. Es wird einer ausführlichen Erforschung der Stammzellen 
und ihrer Eigenschaften und ein noch besseres Verständnis der im kranken Gewebe 
ablaufenden Prozesse bedürfen, um die schon jetzt geplanten ersten menschlichen Tests 
begründen zu können. Mit der Hoffnung der Patienten sollte man dabei ebenso sorgsam 
umgehen wie mit dem Einsatz menschlicher embryonaler Stammzellen. 
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